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When cultured in vitro, human embryonic stem cells (hESCs)
acquire genetic abnormalities that have slowed their therapeutic
use. As hESCs have a “leaky” G1/S boundary, the pressure of
ensuring genetic integrity falls on the G2/M checkpoint, which
can be activated by failed chromosomal decatenation (among other
stimuli). It is hypothesized that hESCs have a deficient
decatenation checkpoint, but little data supports this. Evidence
suggests that the ataxia telangiectasia mutated (ATM) kinase
controls the G2/M decatenation and DNA damage checkpoints,
though previous reports are conflicting on this point. My work
demonstrates that inhibition of decatenation activates ATM and
arrests hESCs in G2. Pharmacologic inhibition of ATM (ATMi)
abrogates this arrest, allowing hESCs to enter mitosis. Live
cell imaging studies reveal that ATMi increases the time it
takes to complete mitosis. Culture of cells under ATMi causes a
gain of DNA content, which is reversed once ATMi is relieved.
BRCA1, a known target of ATM, is also involved in the G2/M
checkpoint. Experimental evidence reveals that activated ATM
phosphorylates BRCA1, preventing Aurora A from interacting with
and phosphorylating BRCA1 on S308, a modification necessary for
mitotic entry. Together, this data illuminates a novel pathway
by which ATM activation mediates G2 arrest in hESCs.

Chapter 1:
Introduction to Embryonic Stem Cells

“Progress in basic developmental is now extremely rapid; human
embryonic stem cells will link this progress even more closely
to the prevention and treatment of human disease.”
- James A. Thomson

1

Embryonic stem (ES) cells, derived from the inner cell mass
(ICM) of a pre-implantation blastocyst, promise advances in
developmental biology, drug discovery, and regenerative medicine
that other cell lines cannot. Proposed breakthroughs come from
the stem cell’s defining property: pluripotency, or the ability
to differentiate and form all three germ layers of the human
body – the endoderm, mesoderm, and ectoderm (Figure 1.1). This
differentiation down specific lineages takes place through
symmetric or asymmetric division. Symmetric division generates a
virtually unlimited supply of pluripotent cells, whereas
asymmetric division produces one pluripotent cell and one
differentiated cell. ES cells, first isolated from standard
laboratory animals and later, from humans, have been a source of
much controversy and debate. While their scientific potential is
widely acknowledged, practical therapies have yet to develop.
Though politics and public opinion have played a part, there are
significant hurdles to overcome in the laboratory before novel
treatments can be brought to the clinic.

Much of the work done on human embryonic stem cells (hESCs) has
been based on studies done in mouse embryonic stem cells
(mESCs). For years, the major method for isolating cells from
the ICM of mouse blastocysts involved complicated and timeconsuming microsurgical methods. In 1975, Solter and Knowles,
2
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interested in studying the immunological maternal-embryonic
relationship, discovered a method for large-scale collection of
cells from the ICM. They isolated blastocysts by flushing them
from the uterine horns on the fourth day of pregnancy,
chemically removing the zonae pellucidae, exposing the
blastocysts to specialized anti-serum and complement, then
removing the damaged trophoblastic layer by pipetting the
blastocysts through a small-bore glass pipette (Solter and
Knowles, 1975). After isolating the ICM, they plated the cells
and described their appearance as such:

“Inner cell masses plated in plastic dishes developed along two
morphological routes: approximately half attached to the surface
and from them relatively large polygonal cells with small
vacuoles began to grow. Outgrowth of trophoblastic cells was
never observed. The central mass of cells then either continued
to grow as a solid mass and eventually developed into a
structure resembling a 7-day-old mouse embryo, or it spread and
formed a monolayer composed of several cell types. Half of the
inner cell masses did not attach but continued to grow, floating
in the medium, forming embryoid bodies with a clearly visible
outer cell layer and a solid mass of cells inside.”

4

These descriptions are characteristic of pluripotent stem cells,
though no such statements were made. The authors conclude their
study by asserting that their technique is an effective method
for the isolation of large numbers of ICM’s (Solter and Knowles,
1975), thus setting the stage for future work in stem cell
research. However, it would still be several years before
pluripotent cells would be successfully propagated in vitro.

The first report of establishing a line of pluripotent cells
from mouse blastocysts was published in 1981 (Evans and Kaufman,
1981). There had been several previous attempts to establish a
stable cell line (Atienza-Samols and Sherman, 1978; Cole and
Paul, 2008; Sherman, 1975; Solter and Knowles, 1975), but none
were successful. It was hypothesized that sustained, successful
culture of pluripotent cells would depend on three factors: 1)
pluripotent cells exist in an embryo which could be propagated
in vitro, 2) it is possible to harvest these cells from the
embryo, and 3) tissue culture conditions could be developed to
encourage expansion, not differentiation of pluripotent cells
(Evans and Kaufman, 1981). To support their hypothesis,
researchers harvested blastocysts from mice and cultured them in
groups of approximately six embryos for four days. The
blastocysts attached to the dish within 48 hours, and the ICM
developed into “large egg cylinder-like structures”, which were
5

picked, dispersed with trypsin, and passaged onto Petri dishes
coated with mitomycin C-inactivated STO fibroblasts (Evans and
Kaufman, 1981). The isolated and expanded cells were found to
have a normal karyotype and key traits of pluripotent cells, and
were able to survive ~30 passages (at the time of publication)
(Evans and Kaufman, 1981). The successful acquisition and
expansion of a stable mESC line set the stage for over two
decades of work before the first non-human primate embryonic
stem cells were derived.

While the isolation and ex vivo expansion of mESCs represented a
major step forward and catalyzed an avalanche of groundbreaking
research, there are enough differences between human and mouse
embryonic development that scientists wondered if the
conclusions drawn from mESC research would accurately reflect
the processes that occurs in humans. After all, the overall goal
was (and is) to use this type of cell in regenerative medicine.
If novel therapies were to develop, then a more appropriate
model needed to be established. To that end, James Thomson,
working out of the University of Wisconsin, set out to create
embryonic stem cells using an organism which more closely
resembled a human: the rhesus monkey. Using the
antiserum/complement technique developed twenty years before
(Solter and Knowles, 1975), Thomson and colleagues successfully
6

isolated and expanded primate embryonic stem cells (Thomson et
al., 1995). As hypothesized, there were several major
differences between these cells and mESCs (see Table 1.1 for a
summary of these differences). The differences in the
fundamental biology of stem cells were significant enough that
the authors concluded that for embryonic stem cells to have a
future in regenerative medicine, primate or, ideally, human
embryonic stem cells would need to be used (Thomson et al.,
1995). In fact, the year before had seen a paper published where
ICM-derived cells from spare in vitro fertilization human
embryos were isolated and cultured. However, while pluripotent
cells were detected, they did not survive beyond two passages
(Bongso et al., 1994). It was clear that the field of embryonic
stem cell research was moving into humans, and it would be the
Thomson group that would eventually take it there.

The first description of the isolation and culture of hESCs was
published in 1998. Thomson and his colleagues collected fresh or
frozen cleavage stage embryos which were produced by in vitro
fertilization for clinical purposes (Thomson et al., 1998).
Importantly, they achieved informed consent from both the donors
and their University’s Institutional Review Board. Using the
same technique which was developed to isolate pluripotent cells
from rhesus monkeys, Thomson’s group ultimately isolated 14
7
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human ICMs and derived from five embryonic stem cell lines
originating from five separate embryos. Importantly, these newly
derived hESCs expressed high levels of telomerase, the enzyme
responsible for producing telomeres (Thomson et al., 1998).
Telomeres are short, repetitive stretches of DNA composed of the
nucleotide sequence TTAGGG, which function to preserve the
structural integrity of each chromosomal end (Hall and Giaccia,
2012). Telomeres act as a “capping mechanism”, ensuring that the
ends of each chromosome are not inappropriately chewed back by
exonucleases, thus distinguishing the ends from double-strand
breaks (which the cell would attempt to repair) (Lundblad,
2000). As somatic cells divide, each successive division results
in marginally shortened telomeres. Once the telomeres reach a
critical length, growth stops and cells either become senescent
or die (Hall and Giaccia, 2012). The expression of telomerase in
hESCs effectively renders them immortal, adding to their allure
for use in medical research. These newly described hESCs were
remarkably similar to the primate embryonic stem cells, and
showed similar contrasts to mESCs (see Table 1.1)(Thomson et
al., 1998). The successful creation of hESC lines promised rapid
advancement for our understanding of a variety of diseases,
however, a myriad of ethical and political controversies would
surround these cells and significantly limit their use for the
next decade.
9

The controversy over public funding for embryonic research

The ethical debate over the use of human reproductive tissues
for medical research has been ongoing since the late 1970s, when
it became clear that biomedical science was entering an era
where these tissues could, and would, be used routinely in the
laboratory setting (Gottweis, 2010). This debate eventually
resulted in an outright ban on government support for any form
of fetal research from 1988-1993 (Wertz, 2002). However, private
funding was still allowed, creating an odd environment in which
controversial research could take place, virtually unregulated
in the private sector, but publically funded research was
effectively rendered illegal. This ban was lifted by President
Clinton in 1993, which resulted in the National Institutes of
Health (NIH) forming the Human Embryo Research Panel (HERP), a
division responsible for creating guidelines mandating
appropriate and inappropriate areas of embryonic research
(Tauer, 1997). While HERP decided that it was acceptable to
conduct research on “leftover” embryos from in vitro
fertilization, Congress, via the Department of Health and Human
Services appropriations process, decreed that “any activity
involving the creation of, destruction of, or exposure to risk
of injury or death to human embryos for research purposes may

10

not be supported with federal funds” (Gottweis, 2010). While
public funds were now freed up to sponsor stem cell research,
support was still coming solely from the private sector until
the end of 1999, chiefly from the Geron Corporation and Advanced
Cell Technology (Annas et al., 1999). In late 2000, the NIH
published guidelines for stem cell research, and almost a year
later, President Bush laid out a governmental policy which
permitted public funding for hESC research using only preexisting cell lines (which were derived using private funds)
(stemcells.nih.gov/policy/pages/2001policy.aspx). In early 2009,
President Obama significantly expanded the scope of cell lines
which could be supported by public funds with the Executive
order “Removing Barriers to Responsible Scientific Research
Involving Human Stem Cells”
(stemcells.nih.gov/policy/pages/2009guidelines.aspx). The
effectiveness of this expansion was short lived, however, when a
U.S. district court issued a preliminary injunction banning the
use of federal funding for hESC research in 2010. This ruling
was temporarily put on hold by the U.S. Court of Appeals, and it
was eventually overturned in 2011
(stemcells.nih.gov/staticresources/Sherley_Mem_Op_granting-DefsMot-Summ-J.pdf). While hESC research has currently been allowed
to continue, a more comprehensive and cohesive policy is clearly
needed to streamline the process of hESC research in the U.S.
11

Induced Pluripotent Cells: A Novel Compromise

hESC research presents an interesting quandary – on one hand,
the cells present an almost limitless opportunity for scientific
advancement. On the other hand, the major legal and ethical
controversies surrounding them have significantly limited
progress towards any biomedical breakthroughs. To this end,
researchers have been attempting to find a work-around for
creating pluripotent cells from sources other than human
embryos. This has two major advantages: 1) the use of human
embryos can be avoided and 2) potential histo-compatibility
problems can be solved (e.g. “growing” a new pancreas for a
diabetic patient, only to have it rejected because the ES cells
used had the wrong antigenic markers).

Investigators have been experimenting with cellular
reprogramming for decades. The first success came in 1952 when
researchers demonstrated that taking nuclei from blastula-stage
embryos and transplanting them into enucleated frog eggs
resulted in normal, hatched tadpoles (Briggs and King, 1952).
This “nuclear transfer” method would be used extensively and
eventually result in the successful somatic cloning of many
different species (the most notable of which was “Dolly” the
sheep) (Wilmut et al., 1997). However, this technique is still
12

limited in humans by the requirement for oocytes, thus not
completely circumventing the issue of the use of reproductive
tissues.

Another method for cellular reprogramming is the fusion of ES
cells with differentiated cells, somehow forcing the somatic
cells back through to a pluripotent stage. This process has been
demonstrated in both mice (Tada et al., 2001) and humans (Cowan
et al., 2005). However, the molecular mechanisms behind this
process are not fully understood, and it has not yet been
clarified if these fusion-transformed cells are 100% pluripotent
(Yamanaka, 2007).

An interesting (if little studied) method developed for this
process is spontaneous reprogramming by culture. For example, it
has been shown that long-term culture of bone marrow-derived
cells can induce pluripotency (Jiang et al., 2002), as well as
the prolonged culture of germline stem cells from mouse testes
(Kanatsu-Shinohara et al., 2004). Strongly limiting this
technique is supporting evidence for the generality,
reproducibility, and yield of pluripotent cells. Additionally,
relying on long-term culture to produce pluripotent cells in any
quantity sufficient enough for regenerative medicine is a
prohibitive barrier.
13

The most recent, and most promising, development for the
creation of reprogrammed somatic cells is the four-factor
transformation method developed by Takahashi and Yamanaka in
2006. These de-differentiated cells were termed induced
pluripotent stem (iPS) cells. Yamanaka’s group identified
twenty-four transcription factors which, when transduced into
mouse fibroblasts, resulted in the creation of (albeit rarely)
colonies of pluripotent cells. Through trial-and-error they
narrowed down the twenty-four transcription factors into four:
Oct3/4, Sox2, Klf4, and c-Myc (Takahashi and Yamanaka, 2006).
The next year, both Yamanaka and another laboratory used the
same technique to create human iPS cells (Takahashi et al.,
2007; Yu et al., 2007).

In his 2007 review, Shinya Yamanaka proposed a model by which
these four key transcription factors work together to promote
pluripotency. c-Myc overexpression, in isolation, can cause p53dependent apoptosis in primary cells. However, KLF4 expression
can suppress p53, thereby preventing cell death. On the other
hand, KLF4 can activate p21, which suppresses cell
proliferation, and c-Myc in turn suppresses p21. The cell needs
to strike a balance between the expression and interaction
between c-Myc and KLF4 in order to remain viable. Additionally,
14

c-Myc can “loosen” the chromatin architecture, potentially
opening up promoters for other genes/proteins important in
pluripotency (Meshorer et al., 2006). However, just expressing
c-Myc and KLF4 would direct cells towards a cancerous fate, not
an embryonic stem cell phenotype. Oct-3/4 and Sox2 likely come
into play here, activating multiple genes important for
pluripotency (and not malignancy). Yamanaka hypothesizes that
the c-Myc-mediated opening of chromatin facilitates Oct-3/4’s
and Sox2’s ability to activate the appropriate genes (Yamanaka,
2007). The balance of factors required for pluripotency appears
both elegant and delicate, and much work remains to be done in
this area to enhance our understanding.

Since this groundbreaking work, several other methods have been
developed based around the four key transcription factors. This
work was spurred on by concern over Yamanaka’s use of retroviral
transduction, causing permanent genomic alteration. The
retroviral integration can lead to tumor development, as well as
continued expression of pluripotent factors in cells derived
from iPS cells (Yu et al., 2009). The first modified
transformation protocol involved using non-integrating
adenoviruses transiently expressing the four key pluripotency
factors (Stadtfeld et al., 2008). Later, a separate group
demonstrated successful transformation using purified
15

recombinant proteins (though this work was done in mice) (Zhou
et al., 2009). Along these same lines, a third group achieved
de-differentiation using synthetic mRNA, which was modified to
overcome innate cellular antiviral responses (Warren et al.,
2010). These so-called “RNA-induced pluripotent stem cells” were
able to be efficiently directed down a new lineage,
differentiating into myogenic cells (Warren et al., 2010).
Though still in its infancy, this work promises to bring the
advantages of iPS cells without the limitations of using
integrating retroviruses.

iPS cells hold several advantages over hESCs, beyond the ethical
and immunogenicity factors. One of the most promising uses of
these cells is in disease modeling. There have been several
papers published describing the reprogramming of diseased cells
in order to gain a greater understanding of their underlying
biochemistry (see (Cherry and Daley, 2012) and (Park et al.,
2008) for example). The use of iPS cells is exciting because one
could theoretically create cells from both diseased and healthy
individuals (within the same family), leading to the study of
genetic variants that could both positively and negatively
affect the development of diseases, as well as disease outcomes
(Ferreira and Mostajo-Radji, 2013). The most interesting
demonstration of the power of iPS cells came out of Rudolf
16

Jaenisch’s lab in 2007. Jaenisch’s group, using a mouse model of
sickle-cell anemia, first harvested fibroblasts which contained
the mutant hemoglobin gene. They then transformed the
fibroblasts into iPS cells, corrected the mutation,
differentiated the cells into blood progenitors, ablated the
bone marrow in experimental mice, and transplanted the corrected
progenitors into the sickle-cell mice. This process resulted in
a lasting cure for the diseased mice (Hanna et al., 2007).
Techniques such as this could be adapted and improved, providing
similar therapies for human patients.

As with any new technology, there are several limitations to
adapting iPS cells for therapeutic use. Yamanaka’s original
paper complains of the ultra-low frequency of transformation
(Takahashi and Yamanaka, 2006), which could present a barrier to
growing a large enough population for use in regenerative
medicine. As mentioned earlier, some of the techniques for
creating pluripotent cells involve the use of integrating
retroviruses, which have tumorigenic potential. This potential
is expounded upon when one of the transduced factors is c-Myc, a
commonly overexpressed oncogene. Interestingly, c-Myc can be
removed and pluripotency achieved with only the three other
factors, but this technique is significantly slower (Wernig et
al., 2008). One study also reported that transplanted autologous
17

iPS cells could induce a T cell-mediated immune response, where
autologous ES cells could not (Zhao et al., 2011). Finally,
human iPS cells have been found to frequently develop
chromosomal aberrations, which could be attributed to
adaptations to prolonged culturing (Mayshar et al., 2010). The
acquisition of aneuploidy, and genomic instability in general,
haunts traditionally derived ES cells as well. These unwanted
genetic alterations have significantly affected efforts to bring
pluripotent cells out of the lab and into the clinic.

18

Genomic Instability: An Unfortunate Hallmark of Pluripotency

The first reports of hESC studies reported a diploid, normal
karyotype (Amit et al., 2000; Reubinoff et al., 2000; Thomson et
al., 1998). However, it was quickly discovered that prolonged ex
vivo culturing and expansion of ICM-derived cells caused them to
become aneuploid (Draper et al., 2004). There are several
theories as to how cells become aneuploid; however, the
breakage-fusion-bridge model is the most widely accepted (see
Figure 1.2). In this model, cells either experience an
unrepaired double-strand break (DSB) or a telomere is degraded
enough that it is sufficiently similar to a DSB. This lesion is
duplicated during S-phase and the two broken chromosomes fuse,
or the cell is unlucky enough to have a separate chromosome that
also has an exposed end. In either case, the broken chromosomes
fuse, creating a chromosome with at least two centromeres
(termed a “dicentric” chromosome). Additionally, there can be a
failed attempt at homologous recombination between two nonhomologous chromosomes which then become stuck together.
Whatever the cause, when these multi-centric (“bridged”)
chromosomes enter mitosis, they are ripped apart during
anapahase (“breakage”), once again

leaving an exposed end that

can fuse with another chromosome. This cycle is then repeated
(for a more extensive review, see (Morgan, 2007)).
19
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Normally, cells that experience such chromosomal aberrations
will die. However, certain structural changes (and a gain or
loss of certain genes) can provide a growth advantage, causing
the mutant cell to eventually overtake the in vitro population
(or, in the case of an organism, cause tumor formation).
Unfortunately, evidence suggests that both hES and iPS cells are
prone to genetic abnormalities almost from the beginning. In the
case of pre-implantation stage embryos, it has been estimated
that as many as 30-65% of cells are already aneuploid (Wilton,
2002). In a recent study, it was found that certain lines of iPS
cells became aneuploid shortly after pluripotency was
established (while the parental cells were determined to be
euploid) (Kim et al., 2009).

While pluripotent cells can be aneuploid from the start, it is
far more common for them to develop abnormalities when cultured
for a long time. This has been most extensively studied in
hESCs. In 2004, a collaborative paper was published (between the
University of Sheffield and the University of Wisconsin)
describing hESCs which eventually (and independently) developed
trisomy of chromosomes 12 and 17 (Draper et al., 2004). There
are several competing (or complementary) theories as to how
prolonged culture can promote the development of aneuploidy
(reviewed extensively in (Baker et al., 2007)). First, and most
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importantly, the technique each lab uses to culture pluripotent
cells can have a major impact on whether or not genomic
instability occurs. One study found that cells passaged using
manual dissection (selecting and transferring colonies by
deliberate choice) were able to maintain euploid karyotypes
after ~105 passages, whereas bulk passaging methods (trypsin,
collagenase, etc.) witnessed the development of aneuploidy after
23-45 passages (Mitalipova et al., 2005). However, since that
study was published, methods have been developed to preserve a
normal karyotype while bulk-passaging ES cells using enzymatic
techniques (Suemori et al., 2006). Another theory of aneuploid
development is the different oxygen tensions pluripotent cells
experience in vitro vs. their in vivo environment.

Cells in

culture are kept at a significantly higher oxygen tension than
what they would experience in the body, and this, in turn, has
significant effects on development (see (Harvey, 2007), for
example). High oxygen tension has been found to cause damage in
both nuclear and mitochondrial DNA (von Zglinicki et al., 2000),
and studies in hESCs have found mutations in mitochondrial DNA
after prolonged culture under high oxygen conditions (Maitra et
al., 2005), supporting the notion that oxygen levels influence
genomic stability.

Finally, there are several additional factors which may
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influence survival and karyotype preservation, but these factors
are difficult to dissect out and directly study. hESCs are
widely disseminated through large cell banks; the freeze-thaw
cycles which these cells undergo may inadvertently select for
abnormal cells which can withstand these processes best. The
method of culture (beyond the question of passaging) may also
select for abnormal cells with a growth advantage. Laboratories
have (for the most part) transitioned from using inactivated MEF
feeder layers and homemade media to artificial substrates
(Matrigel) with defined, proprietary media (i.e. mTeSR-1 and-2
from Stem Cell Technologies, or StemLine from Sigma-Aldrich).
These newer, xenobiotic-free and extensively studied ingredients
may help alleviate the problems associated with the originally
developed methods.

Pluripotent stem cells, both ICM-derived and artificially
induced, harbor exceptional potential for developing therapeutic
advances for many diseases. However, use of these cells has been
hampered through legal and ethical quandaries, as well as the
common acquisition of genetic abnormalities (e.g., aneuploidy)
when expanded in the laboratory. As these abnormalities can
catalyze neoplastic progression, the genomic instability
inherent to in vitro work has slowed efforts to bring PSCs from
the bench to the bedside. Though hESCs were first described
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fifteen years ago, there have only been five clinical trials
established (or planned) using these cells (see Table 1.2).
Obviously, a greater understanding of the basic biology of
pluripotent cells is necessary to advance their use in the
clinic. Specifically, elucidating mechanisms of cell cycle
control in pluripotent cells could reveal novel approaches to
enhance the preservation of genomic integrity.
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Chapter 2:
Cell Cycle Control
in
Human Embryonic Stem Cells
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Actively growing cells consist of four distinct phases: G1, S,
G2, and M. Cells synthesize new DNA and separate this duplicated
genetic information into two different cells; these phases are
referred to as “S” and “M”, respectively. The “gap” phases, G1
and G2, either produce the appropriate proteins for cells to
replicate their genome (G1), or prepare the cell to divide (G2).
These events and phases must be tightly orchestrated and
regulated in order to ensure the appropriate growth and division
of each cell. To this end, cells have evolved specific
restriction points, termed “cell cycle checkpoints”, which exist
solely to monitor progression through the cell cycle, and allow
the cell to move to the next phase if everything has occurred
appropriately. If an error is detected, these checkpoints
activate and growth is arrested.

While biologists have been aware of distinct phases in the life
cycle of the cell for many years (i.e., (Boveri, 1902)), it
wasn’t until 1970 that the molecular mechanisms of cycle control
began to be elucidated by Leland Hartwell (Hartwell 1970). This
work was expanded upon by Paul Nurse (see (Nurse and Thuriaux,
1980) or (Nurse and Bissett, 1981) , for example) and Tim Hunt
(Evans et al., 1983). Their efforts were eventually recognized
in 2001, when all three investigators were awarded the Nobel
Prize in Physiology or Medicine.
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Once embryonic stem cells came into the scientific arena,
attention was focused on their cell cycle, both out of general
curiosity and practical purpose: if pluripotent stem cells
commonly develop karyotypic abnormalities (despite having a
lower mutational rate (Tichy, 2011)), perhaps their cell cycle
checkpoints weren’t as robust as their differentiated
counterparts. Indeed, these cells, in vivo, only exist for a few
days – where is the evolutionary pressure for them to have
stringent cell cycle control (for perspective, see (Damelin and
Bestor, 2007))?

It was quickly discovered that ES cells have a

common – though atypical – cell cycle structure. This structure
gives us intriguing insights into the molecular mechanisms of
genomic fidelity in pluripotent cells.

This chapter will be broken down into two sections. First, the
three major cell cycle checkpoints (G1/S, intra-S, and G2/M)
will be discussed in the context of both differentiated and
pluripotent cells. Second, three major proteins will be
discussed in the context of their role in cell cycle checkpoint
control: ataxia-telangiectasia mutated (ATM), breast cancer gene
1 (BRCA1), and Aurora A.
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G1 and the G1/S Checkpoint

The G1 phase of the cell cycle exists to produce proteins both
for cellular function, as well as to prepare the cell to
duplicate its DNA in S phase. In normally functioning
differentiated cells, prior to commitment to entering S phase,
the Rb (retinoblastoma) protein exists in a hypo-phosphorylated
state (van den Heuvel and Dyson, 2008). This hypo-phosphorylated
Rb binds to the E2F-DP1 transcription factors, and this complex
then goes on to bind to and form a large, inhibitory complex
with HDAC (van den Heuvel and Dyson, 2008). Once the cell has
prepared adequately to enter S, Rb becomes phosphorylated via
the kinase action of the Cyclin D-CDK4/6 and Cyclin E-CDK2
moieties, which breaks up the Rb-E2F-DP1-HDAC inhibitory
complex, allowing the cells to bypass the G1/S checkpoint and
enter S phase (Morgan, 2007).

If everything doesn’t go according to plan, the cell can
activate the G1/S checkpoint and halt growth. There are several
events which can activate this first cellular barrier. If DNA
damage is detected, the key phosphatase cdc25A (responsible for
removing inhibitory phosphorylations on the Cyclin E-CDK2
complex) becomes ubiquitinated by the SCF ubiquitin ligase
moiety (downstream of the ATM/ATR/Chk pathway, which will be
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discussed further), and is thusly degraded (Morgan, 2007; Skaar
and Pagano, 2009). Without cdc25A removing inhibitory
phosphorylations, Cyclin E-CDK2 does not become active, and the
cell cannot enter S phase.

DNA damage also activates the p53

pathway, arguably the most studied protein pathway in Cancer
Biology (to be discussed later in this section). Treatment with
TGF- β (transforming growth factor beta), a secreted protein
which controls cellular proliferation (among other functions),
can also activate the G1/S checkpoint through inhibition of
cdc25A transcription via its ability to enhance p21 synthesis
(Hanahan and Weinberg, 2000). Finally, the checkpoint can be
activated by removal of growth factors from the media. Growth
factor removal activates GSK-3β (Glycogen synthase kinase 3
beta), which in turn phosphorylates Cyclin D, leading to the
cyclin’s ubiquitination and proteasomal degradation (Diehl et
al., 1998). Together, these events serve to ensure that the cell
does not inappropriately enter the next phase of the cell cycle.

ES cells, both mouse and human, contain several distinctions
from their more differentiated counterparts in regards to the G1
phase and the G1/S checkpoint. Several studies have demonstrated
that ES cells have an abbreviated G1 phase (Becker et al., 2010;
Filipczyk et al., 2007; Neganova et al., 2008). In mice, it was
found that Rb is hyper- and constitutively-phosphorylated, which
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keeps it in an inactive state (Burdon et al., 2002; Koledova et
al., 2010).

In one study of hESCs, the Cyclin D-CDK4 complex was
consistently up-regulated, and this was a hypothesized cause for
the observed shortened G1 phase (Becker et al., 2006).
Conversely, a second group of investigators found that hESCs did
not have D-type cyclins (Filipczyk et al., 2007). However, they
did contain high levels of Cyclin E, another protein important
for progression through G1. In opposition to these two models,
other researchers have found that there are fluctuating levels
of Cyclin E in hESCs, stable levels of Cyclin D, with all the
appropriate CDKs present and active (Barta et al., 2013;
Neganova et al., 2008). These same groups have found that CDK2,
Cyclin A, Cyclin E, and cdc25A are all highly expressed in
hESCs. While several labs have published contradictory results,
these differences could be due to the fact that they all used
different cell lines. What was universally demonstrated,
however, was that ES cells are distinct from their somatic
offspring.

In regards to the G1/S checkpoint, it has been repeatedly
demonstrated by independent labs and investigators that both
human and mouse ES cells lack an active p53-p21 pathway (Bárta
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et al., 2010; Filion et al., 2009; Momcilović et al., 2009). In
normal cells, p53 is bound to another protein, MDM2 (mouse
double minute 2 homolog), and kept in an inactive state (both by
MDM2 transporting it to the cytosol and ubiquitinating it for
proteasomal degradation (Moll and Petrenko, 2003)). In response
to genotoxic events, p53 is activated through two major
modifications: phosphorylation of MDM2, as well as p53 itself.
MDM2 is phosphorylated by ATM on Ser395 and by c-Abl on Tyr394
(Brooks and Gu, 2010). p53 is phosphorylated by ATM, ATR, Chk1,
Chk2, and DNA-PK on Ser15 and Ser20 (Brooks and Gu, 2010). These
phosphorylations serve to break the inhibitory MDM2-p53
interaction, then stabilize and activate p53. Activated p53 goes
on to enforce the G1/S checkpoint (among many other actions) by
promoting the transcription of p21, a potent cell cycle kinase
inhibitor. After translation, p21 binds to and inhibits the
Cyclin-CDK2 and –CDK4 complexes, thus preventing the entrance
into S phase (Sancar et al., 2004).

The p53/MDM2/p21 story is heavily studied and documented over a
wide range of cell types, which makes the lack of this pathway
in hESCs so interesting. For years, the non-functional p53
pathway meant that there was no known effective G1/S checkpoint
in pluripotent cells. However, in 2010, Bárta and colleagues
discovered that there was indeed a G1/S checkpoint in hESCs, and
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that it could be activated by low-dose UV-C radiation (Bárta et
al., 2010). This G1 checkpoint was not mediated by p53
activation. Instead, the extremely rapid degradation of cdc25A
seemed to be the cause (Bárta et al., 2010).

Interestingly, the

investigators did see an increase in the levels of phospho-p53
(and p53 levels in general), which did, in turn, cause an
increase in the levels of p21 mRNA. However, this increase in
p21 mRNA did not lead to an increase in the p21 protein. Upon
further experimentation, it was discovered that pluripotent
cells were expressing miR-302s, and these micro-RNAs were
preventing the translation of p21 (Dolezalova et al., 2012).

In

fact, it appears that the increased translation of p21 in
pluripotent cells, instead of (or complementary to) enacting the
G1/S checkpoint, causes differentiation of the cells. This was
discovered after artificially stabilizing p53 for long periods
with Nutlin (Maimets et al., 2008). It was also found that
decreasing Oct4 levels (a transcription factor important for
pluripotency) also increases p21 levels and thus,
differentiation (Greco et al., 2007; Lee et al., 2010).

Though it was thought for many years that human and mouse ES
cells did not have a G1/S checkpoint, more recent work has cast
doubt onto that hypothesis. However, while stem cells can
activate a G1 checkpoint through cdc25A degradation, this arrest
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appears “leaky”. Experiments with BrdU incorporation (and other
assays) have found that damaged hESCs still enter S phase at an
appreciable rate (Bárta et al., 2010; Hyka-Nouspikel et al.,
2012; Lee et al., 2010; Momcilović et al., 2009). This is
disquieting, as most other cell types would stringently arrest
before DNA replication to prevent the propagation of genomic
errors. This leaky checkpoint puts pressure on the other phases
of the cell cycle to catch what it erroneously allows to pass.
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S Phase and the Intra-S Checkpoint

If genomic lesions make it past the G1/S checkpoint, these
insults can be replicated and turned into heritable mutations.
Therefore, cells have evolved an intra-S phase checkpoint to
attempt to prevent this from happening. The S phase checkpoint
can be considered the last line of defense, as it functions to
prevent cells from duplicating genomic errors acquired in, or
before, S phase. Traditional activators of the intra-S
checkpoint include replication stress, nucleotide excision
repair, or resected breaks in DNA (Chen et al., 2012). The term
“replication stress” usually refers to stalled replication
forks.

Fork progress is halted when the replication complex

encounters a genetic lesion. When the fork comes to a break, one
DNA polymerase enzyme will arrest while the other continues on
(Smith et al., 2010).

The most heavily studied pathway controlling this checkpoint
involves the ataxia-telangiectasia and Rad3-related (ATR) and
Chk1 kinases. Experimental investigations have found that
homozygous deletion of either the ATR or Chk1 genes results in
peri-implantation embryonic lethality at embryonic day 7 (Brown
and Baltimore, 2000; Garrett and Collins, 2011) for ATR and
between days 3.5 - 7.5 (Takai et al., 2000) for Chk1. The only
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known viable mutation of ATR in humans results in Seckel
syndrome, which is characterized (as are many other disorders
relating to DNA damage response protein mutations) by growth
retardation and microcephaly (O’Driscoll et al., 2003).

The intra-S checkpoint, as mediated by ATR, is activated when a
stalled fork causes an excessive amount of single-strand DNA
formation. This single-stranded DNA is immediately coated by RPA
(replication protein A), which recruits ATR to the area via the
ATR-interacting protein (ATRIP), a regulatory complex which
enhances ATR binding and activity (Chen et al., 2012). ATR, once
recruited to the lesion, becomes activated and phosphorylates
Chk1 on Serine 317 and Serine 345. Serine 345 phosphorylation is
essential for Chk1 activation (Takemura et al., 2006; Wilsker et
al., 2008). Once activated, Chk1 autophosphorylates on Serine
296, which leads to its dissociation from chromatin (Chen et
al., 2012). Chk1 then goes on to phosphorylate and inhibit
cdc25A (in the case of the intra-S checkpoint) or cdc25C (in the
case of the G2/M checkpoint).

As eukaryotic DNA replication occurs throughout S phase via
multiple origins of replication distributed across the genome,
proper regulation of S phase involves the surveillance of both
the firing of individual origins and replication fork
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progression after initiation. Due to the complexity of this
process, there is considerable debate in the field over exactly
how the intra-S checkpoint exerts its control over the cell
cycle. For the most part, it appears to be less of an absolute
arrest of cell activity, and more of a delay/slowing in S-phase
progression (Ge and Blow, 2010; Ge et al., 2007; Grallert and
Boye, 2008). Currently, it appears that the intra-S checkpoint
represses late-origin firing (Grallert and Boye, 2008), while
not preventing new fork initiation at sites very close to
whatever genetic defect activated the checkpoint (Labib and De
Piccoli, 2011).

There has been very little study of the intra-S phase checkpoint
in pluripotent cells, whether it is in mouse, human, or
otherwise. This is surprising, given that ~60% of ES cells are
in S phase at any given moment (Savatier et al., 2002), and, as
previously discussed, these cells lack a strong G1/S checkpoint.
However, one group specifically investigated the intra-S
checkpoint of mESCs back in 2005. They discovered that treating
cells with caffeine, a known inhibitor of both the ATM and ATR
kinases, resulted in an S-phase delay and apoptosis (Jirmanova
et al., 2005). Interestingly, during the course of these
experiments, Jirmanova et al found that basal ATM and ATR kinase
activity was relatively high. This is in direct contrast to
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previous studies, where it was demonstrated that terminally
differentiated cells had virtually no basal ATM/ATR activity,
but treatment with irradiation caused rapid activation
(Bakkenist and Kastan, 2003). To tease out which kinase was
important for S-phase progression, Jirmanova and colleagues
treated cells with caffeine (at a dose sufficient to inhibit
ATR) or wortmanin, at a dose sufficient to inhibit ATM (but not
ATR). It was found that inhibition of ATR, not ATM, was what
caused the S-phase delay (Jirmanova et al., 2005). Seeking to
elucidate this pathway further, they created p38α knockout
cells. A prototypical stress-activated protein kinase, p38α is
known to play a role in the cell cycle (for review, see (Duch et
al., 2012)). Using these cells and caffeine, it was found that
inhibition of ATR activates a p38α-p21 pathway which triggers
the intra-S checkpoint. While p21 was increased, researchers
failed to find any increase in p53 levels or activity,
suggesting this arrest was solely due to the ATR- p38α
interaction (Jirmanova et al., 2005).

The only study done on S-phase checkpoints using human cells was
performed with embryonal carcinoma (EC) cells. The authors
justified their use in lieu of, and generalized their findings
to, hESCs because “EC cells have some similarities to ES cells
in terms of karyotypic changes, adaptation to culture, and
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teratoma formation” (Mackenzie, 2006; Wang et al., 2009). They
mostly compared checkpoint response in undifferentiated vs.
retinoic acid-differentiated EC cells. Wang et al found that
undifferentiated cells survived better and had more efficient
DNA repair after irradiation compared to their differentiated
counterparts (Wang et al., 2009).

Additionally, the

undifferentiated EC cells showed an “enhanced” S-phase delay. By
inhibiting Chk1 with the Chk1-specific inhibitor UCN-01, the Sphase checkpoint activation was abolished (Wang et al., 2009).
These results support Jirmanova et al’s data, indicating that,
like their somatic counterparts, pluripotent cells rely on the
ATR-Chk1 axis to mediate S-phase delay.

While only two studies have examined the intra-S checkpoint in
pluripotent cells, it is evident that the signaling pathway used
is similar to differentiated cells. However, given the amount of
time that ES cells spend in S phase, it is surprising that more
researchers haven’t taken on projects investigating the relevant
proteins working to ensure genomic integrity during DNA
replication. It seems that these types of studies are
technically demanding, thus limiting a researcher’s ability (and
motivation) to study the intra-S checkpoint. Regardless, with a
weak G1/S checkpoint, and an S phase checkpoint which only
delays cycle progression (instead of outright arresting it), it
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stands to reason that the final checkpoint before mitosis, the
G2/M checkpoint, must be robust if a cell hopes to accurately
pass on its genetic information.
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G2 and the G2/M Checkpoint(s)

If the G1/S or intra-S checkpoints fail to activate and prevent
cells with genetic lesions from continuing to cycle, the G2/M
checkpoint still stands guard against the creation of abnormal
progeny. Similar to the G1/S checkpoint, the G2/M checkpoint
depends on the activities of cyclins and cyclin-dependent
kinases to function. At this point in the cell cycle, the chief
proteins involved make up the Cyclin B/CDK1 complex. In cells
that aren’t ready to enter mitosis, the Wee1 and Myt1 kinases
phosphorylate CDK1 and keep it in an inactive state. Once the
decision has been made to divide, Aurora A (along with its
cofactor, Bora) activates and phosphorylates Plk1. Once
activated, Plk1, in turn, phosphorylates cdc25C. Activated
cdc25C removes the inhibitory phosphorylations from Cyclin
B/CDK1, and promotes the progression to mitosis (for review, see
(Morgan, 2007)).

However, if the cell notices that something has gone awry in its
normal growth pattern, it has several options available to
arrest growth and prevent the entry into mitosis. Canonically,
DNA damage will activate ATR and ATM, which will activate Chk1
and Chk2 (respectively), which will, among other actions,
phosphorylate cdc25C and target it for destruction (Ciccia and
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Elledge, 2010; Rieder, 2011).

There is a second, little-studied pathway for G2/M arrest
involving the p38 MAP kinase. A member of the mitogen-activated
protein kinase (MAPK) family, there are four isoforms of p38
(alpha and beta are universally expressed, while gamma and delta
have a tissue-specific expression pattern) (Thornton and Rincon,
2009). Many different types of DNA/cellular damaging agents have
been found to activate the p38 checkpoint pathway: drug
treatment with microtubule inhibitors, topoisomerase II
inhibitors, and histone deacetylase inhibitors; excessive
illumination during microscopy experiments, and media changes
(osmotic stress) (Matsusaka and Pines, 2004; Mikhailov et al.,
2004, 2005, 2007; Rieder, 2011). While it is not clear exactly
how p38 is activated in response to DNA damage, it has been
demonstrated that ATM activation is required for p38 activation.
Since there are no ATM phospho-motifs on p38, it has been
hypothesized that ATM signals through the Tao kinases, which can
phosphorylate p38 (Thornton and Rincon, 2009). There does appear
to be some mechanism by which p38 can be activated independently
of ATM, but this activation has not been well characterized
(Mikhailov et al., 2004; Reinhardt et al., 2007). Once
activated, it is believed that p38 phosphorylates MK2, which
then goes on to phosphorylate and inactivate cdc25B, another
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phosphatase important for cell progression through the G2/M
checkpoint (Lemaire et al., 2006; Manke et al., 2005).

Interestingly, there is also a role for p53 in executing the
G2/M checkpoint. Similar to its G1 activities, the ATR/ATM
Chk1/Chk2 signaling pathway can phosphorylate and stabilize p53.
As in G1, activated p53 promotes the transcription and
translation of p21, which will bind to (and prevent from
functioning) the Cyclin B/CDK1 complex (Abbas and Dutta, 2009).
In addition to p21, p53 can also promote the function of the 143-3 complex. This complex will bind to the phosphorylated
version of the Cyclin B/CDK1 complex and export it from the
nucleus (Abbas and Dutta, 2009). Similarly, activated p53 will
also promote GADD45’s binding to the cyclin/CDK complex and
direct those proteins to the cytoplasm (Thornton and Rincon,
2009). It is important to note, however, that studies have
demonstrated that while p53 promotes the G2/M checkpoint, it is
not essential (see (Löbrich and Jeggo, 2007) for discussion).

Classical studies demonstrated that the G2/M checkpoint was
highly sensitive to DNA damage. Working in yeast, researchers
found that a single double strand break (DSB) was sufficient to
arrest cell growth (Bennett et al., 1997). This model was widely
accepted to be the case for mammalian cells as well. However,
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further investigation found this belief to be inaccurate. Using
Artemis-deficient cells (which have a defect in repairing DNA
damage, but no defect in checkpoint activation), researchers
found a “critical threshold” of DSBs which cells would have to
endure before checkpoint activation (Deckbar et al., 2007). This
threshold was approximately 20 DSBs. Deckbar et al found that if
DNA damaging agents caused fewer than 20 DSBs, the G2/M
checkpoint would not activate. If these damaging agents caused
more than 20 breaks, cycling would pause until the cells had
repaired enough damage to get below the critical threshold
(Deckbar et al., 2007). Therefore, there appeared to be a dosedependent length of arrest – the higher the levels of damage,
the longer the cells would remain arrested.

This dose-dependent length of arrest is important, because tumor
cells show a sort of “adaptation” to cell cycle arrest. Was this
threshold model accurate, or were cells, instead of repairing
enough damage to get under the critical 20 DSB threshold, just
adapting to the DNA damage and continue to grow? After all,
under continuous exposure to 6 Gy of IR, tumor cells eventually
break free of arrest and enter mitosis with multiple, unrepaired
breaks (Bartek and Lukas, 2007; Syljuåsen et al., 2006). This
adaptation appears to be mediated by the resumption of Plk1
activity and the inhibition of Chk1 (Bartek and Lukas, 2007;
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Syljuåsen et al., 2006). However, what was observed in these
tumor lines does not appear to be the case for somatic (nonneoplastic) cells. In the Artemis-deficient cells, which could
not repair the DSBs (but were otherwise normal), cell cycle
arrest continued for many days (Deckbar et al., 2007).

Unfortunately, there have been few studies conducted which
directly investigate G2/M checkpoint activation in embryonic
stem cells (though several groups have investigated cancer stem
cell checkpoint function – this will not be discussed). One of
the earliest reports looked at the Akt/Protein kinase B (PKB)
pathway in mESCs. Akt is a critical protein mutated in many
human cancers. It is involved in the regulation of many cellular
functions including metabolism, cell growth, apoptosis and
survival (for review, see (Song et al., 2005)). Using PTEN
knockout mESCs, Kandel and colleagues found that they could
override the G2/M checkpoint after irradiation (PTEN is a
phosphatase responsible for removing activating phosphorylations
from the Akt molecule) (Kandel et al., 2002). They assert that
normal Akt signaling is needed for mESCs to properly transverse
the G2/M checkpoint, however, they offer no pathway/mechanism
for this opinion (Kandel et al., 2002).

Another set of investigators examined the effect of Rad9
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knockout on mESCs. Rad9, together with Rad1 and Hus1, form the
“9-1-1” complex, which functions in DNA repair and activation of
cell cycle checkpoints (Doré et al., 2009; Sohn and Cho, 2009;
Xu et al., 2009; Zhang et al., 2011). The 9-1-1 complex executes
these actions by first being loaded onto damaged chromatin.
After loading, the 9-1-1 complex binds TopBP1, which stimulates
ATR-mediated Chk1 phosphorylation and downstream events (such as
cell cycle arrest) (Delacroix et al., 2007). Zhang et al showed
that Rad1 knockout mESCs were defective in G2/M arrest after
both UV- and gamma-irradiation (Zhang et al., 2011).

Recently, the canonical DNA damage signaling pathway involving
ATM/Chk2/p53 was investigated in hESCs. Using gamma radiation,
Momcilovic et al demonstrated that ATM was phosphorylated and
localized to sites of DSBs within 15 minutes, and that cells
arrested in G2, not G1 (Momcilović et al., 2009). The peak level
of ATM, Chk2, and p53 phosphorylation was seen within 1 hour of
IR. Interestingly, it was observed that the cell cycle arrest
was temporary – after 16 hours, the irradiated cells resumed
proliferation (Momcilović et al., 2009). It was unclear whether
this release was due to the hESCs repairing the damage to get
below the critical threshold of DSBs, or, like tumor cells, they
can eventually overcome the block even in the presence of
significant damage. To confirm that ATM was responsible for
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mediating arrest, Momcilovic et al used the ATM-specific kinase
inhibitor, KU-55933, to pharmacologically inhibit ATM. Treating
with KU-55933, it was observed that the G2 arrest could be
abolished 2 hours after irradiation. Notably, it was observed
that ATM could only be inhibited by using 10x the normal dose
(10 μM is sufficient to inhibit ATM in other cell types, here,
100 μM was used) (Momcilović et al., 2009). This is curious, as
other labs have used KU-55933 to inhibit ATM in hESCs at
standard dosages (Adams et al., 2010a, 2010b). While the authors
claim that KU-55933 at 100 μM should still, theoretically, only
inhibit ATM, it is possible that such a high concentration could
inhibit other kinases involved in the DNA damage response/growth
and proliferation, such as DNA-PK or mTOR (per the IC50 values
provided on www.tocris.com). Further study is warranted in this
area.

While there is a paucity of reports investigating the G2/M
checkpoint in ES cells, it does appear that their mechanisms for
arrest are similar to differentiated cells, at least insofar as
arrest caused by DNA damaging agents. However, DNA damage is not
the only way to cause a G2/M arrest. There is another, distinct
checkpoint which takes place at the border of mitosis – the
decatenation checkpoint.
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The decatenation checkpoint

After replication, daughter chromatids contain areas of
entanglement, or catenations. These catenanes form when two
replication forks meet, and the parental and daughter strands
cannot separate (Downes et al., 1994). The cell must relieve
these catenations for normal replication to complete. If
catenations are not resolved, a distinct G2/M cell cycle
checkpoint activates – the decatenation checkpoint. If the
checkpoint does not activate, nondisjunction and chromosome
breakage can occur, causing genomic aberrations in daughter
cells. Topoisomerase II-α is the enzyme responsible for
decatenation and decatenation checkpoint signaling (Bower et
al., 2010a). Topoisomerase II untangles chromosomes via the same
mechanism by which it relieves helical stress after replication:
by binding to DNA, cutting both stands, passing a second DNA
duplex through the cut, and re-ligating the cut strands (for
review, see (Wang, 2002)).

Failure to adequately decatenate chromosomes activates the
decatenation checkpoint. Currently, the checkpoint signaling
cascade is not well characterized. A hypothesis of the pathway
is given in Figure 2.1. Initial studies of the checkpoint
examined the proteins involved in the DNA damage response
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pathway, ATM and ATR. It was found that ATR, not ATM, mediated
the checkpoint, and that BRCA1 was also involved (Deming et al.,
2002). Interestingly, experimental data indicated that while ATR
was essential for checkpoint activation, it wasn’t acting
through the traditional Chk1 pathway. Instead, it suggested that
ATR mediated the decatenation checkpoint by excluding Cyclin
B/CDK1 complexes from the nucleus through an unknown mechanism
(Deming et al., 2002). A later study using lung cancer cell
lines found that inhibiting decatenation caused
autophosphorylation of ATM, but this finding was not followed up
on (Nakagawa et al., 2004). Recently, studies have surfaced
stating that ATM, not ATR, mediates the checkpoint (Bower et
al., 2010b) (the same group that published the initial,
conflicting paper on ATM/ATR and decatenation checkpoint
signaling), or that ATM and ATR have complementary roles in the
checkpoint (Greer Card et al., 2010).

Murine embryonic stem cells and CD34+ human hematopoietic
progenitor cells were found to have a defective decatenation
checkpoint (Damelin et al., 2005). This defect is hypothesized
to be a cause of the chromosomal aberrations witnessed in
culture (i.e., catenations are not resolved, nondisjunction
occurs during mitosis, and a gain of chromosome 12 or 17 is
acquired, conferring some sort of growth advantage). It is
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theorized that the stem cells harvested from blastocysts and
expanded in vitro have had little selection pressure for
stringent cell cycle regulation, as their in vivo environment
requires few divisions (Damelin and Bestor, 2007).

Unlike the G2/M DNA damage checkpoint, there have been
relatively few papers published on the molecular underpinnings
of the decatenation checkpoint in the nearly 20 years since it
was first described, and the few papers that have been published
present contradictory results. Additionally, the only paper
which examined the decatenation checkpoint in ES cells proposes
a tantalizing mechanism by which aneuploidy could develop in
pluripotent cells. Clearly, more work needs to be done in this
area to enhance our understanding of the decatenation checkpoint
and how manipulation of this pathway can be used to enhance stem
cell genomic integrity.
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Proteins involved in checkpoint signaling

The field of study regarding our molecular understanding of cell
cycle control has exploded since the groundbreaking work done in
the 1970’s. Thousands of manuscripts, books, and doctoral
dissertations have been authored on the intricate protein
signaling networks that govern the growth and genomic integrity
of individual cells. The present work will focus on three
proteins which are known to play key roles in checkpoint
regulation: ATM, BRCA1, and Aurora A. As it is not feasible to
accurately convey the current state of knowledge on each of
these proteins, several references to seminal books and review
papers are given in the following sections.
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Ataxia Telangiectasia Mutated

Ataxia telangiectasia (Online Mendelian Inheritance in Man
(OMIM) database ID: 208900) is a rare disease inherited in an
autosomal recessive manner (Lavin, 2008; Perlman et al., 2012).
Its pathology is characterized by progressive neurodegeneration
(primarily in the cerebellum), telangiectasia (dilation of blood
vessels, mainly around the mouth and eyes), immune deficiency,
thymic and gonadal atrophy, a predisposition to cancer, acute
sensitivity to radiation, growth retardation, premature aging,
and insulin resistance (Shiloh and Ziv, 2013). Typically,
affected patients express a truncated form of ATM or one plagued
by missense mutations. Many of the major symptoms of ataxia
telangiectasia can be attributed to a defective cellular
response to endogenous, physiological DSBs or by exogenous DNA
damaging agents.

The protein responsible for the disease, ATM, is a 350 kDa
protein containing 3,056 amino acid residues. A serine/threonine
kinase, ATM targets and phosphorylates serine-glutamine (SQ)
and/or threonine-glutamine (TQ) motifs on substrate proteins.
Currently, there is a distinct lack of structural information on
ATM, as it has yet to be crystallized (due to the technical
challenge of crystallizing this particular molecule) (see Figure
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2.2 for a schematic of the ATM protein). ATM acts as a
“transducer” of DNA damage, signaling other proteins when damage
is detected. Other protein complexes bind to the lesions first
(the “sensors” of DNA damage) and bring ATM in to activate a
global cellular response to DNA damage (for review, see (Shiloh
and Ziv, 2013)). As discussed in the previous sections, this
signal transduction is crucial to G1/S and G2/M checkpoint
activation.

ATM is a member of the PI3K-like protein kinase family (PIKK).
Two other members of the PIKK family play key roles in the DNA
damage response (DDR) and cell cycle checkpoint signaling: ATR
and DNA-PK (DNA-dependent protein kinase catalytic subunit). ATR
(as discussed earlier) also acts as a signal transducer, often
performing overlapping functions with ATM. DNA-PK is best known
for its role in non-homologous end joining (NHEJ), where it
forms a holoenzyme with the KU-70/KU-80 heterodimer (Hill and
Lee, 2010; Neal and Meek, 2011; Shiloh and Ziv, 2013).
Interestingly, cells from ataxia telangiectasia patients are
able to perform some of functions of the DDR which are known to
be ATM dependent (although in a somewhat diminished capacity)
(Tomimatsu et al., 2009). It is possible that some other
proteins in the PIKK family (like ATR and DNA-PK) can “fill in”
for ATM and take on some of the workload in its absence.
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While there are conflicting reports over exactly how (and what)
activates ATM in response to DNA damage (or other agents - to be
discussed), the most accepted model begins with the
Mre11/Rad50/Nbs1 complex, commonly known as the MRN complex. The
MRN complex is a highly conserved group of proteins shown to
rapidly localize to sites of DNA damage and play an important
role in homologous recombination repair (HRR), NHEJ, and cell
cycle checkpoint signaling (see (Lavin, 2008), for review).
Mre11/Rad50/Nbs1 binds to sites of DSBs and tethers the two
broken ends together. This binding is crucial for the
recruitment and activation of ATM. Under normal conditions, ATM
exists in the cell as an inactive dimer, and, upon recruitment
to sites of DSBs by the MRN complex, activates and dissociates
into two monomers (Bakkenist and Kastan, 2003). During the
activation sequence, ATM is autophosphorylated on Serine 367,
Serine 1893, and Serine 1981 (Czornak et al., 2008) (see Figure
2.2 for a summary of the key activating post-translational
modifications of ATM). While there is conflicting information on
the subject, it is currently hypothesized that ATM’s
autophosphorylation (specifically on Serine 1981) is not
required for its monomerization or recruitment to sites of DSBs,
rather, the autophosphorylation is essential for retention at
sites of genetic lesions (Bensimon et al., 2010; Lee and Paull,
2005; So et al., 2009). However, a group of investigators did
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find evidence supporting the notion that autophosphorylation is
the cause of monomer formation (Bakkenist and Kastan, 2003).

Other evidence-based models have been brought forward suggesting
that the DSB-MRN complex pathway may not tell the entirety of
the story. Michael Kastan’s lab published a report demonstrating
that the conformational change in chromatin, which follows DSB
formation, rather than the DSB itself, is what causes ATM
activation (Bakkenist and Kastan, 2003). A later paper supported
this model by showing that artificial “tethering” of ATM to
chromatin could activate the ATM-dependent DDR (Soutoglou and
Misteli, 2008). In contrast, other work has suggested that ATM
needs to interact with broken DNA to become activated (You et
al., 2007), and that oligonucleotides from resected DSBs have
the ability to activate ATM (Jazayeri et al., 2008). It is
likely, given ATM’s widespread responsibilities in genomic
surveillance, that most, if not all of these models contain some
sort of truth. Further work is needed in this area to clarify
the conditions under which ATM is activated.

Over the past several years, many novel pathways involving ATM
have been described. Investigators have shown that ATM can
activate NF- κB, which promotes the transcription of antiapoptotic genes (Hadian and Krappmann, 2011; Rashi-Elkeles et
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al., 2006). It does this by phosphorylating IKKγ, a subunit of
the IκB kinase (IKK) family (McCool and Miyamoto, 2012). In
unstimulated cells, the IκB proteins inhibit NF- κB by keeping
it sequestered in the cytoplasm. Once IKKγ is phosphorylated and
activated by ATM, it, in turn, phosphorylates IκBα, which leads
to IκB ubiquitination and eventual degradation (Shiloh and Ziv,
2013). Once these inhibitory proteins are degraded, NF-κB is
free to enter the nucleus and begin transcription.

ATM is also involved in the oxidative stress response. Reactive
oxygen species exert their damage by direct oxidation of
cysteine residues, disrupting the structure and function of
important intracellular proteins. However, the oxidation of
certain cysteine residues in ATM catalyzes the formation of
active, disulphide-crosslinked ATM dimers which are then able to
enact a global cellular response to oxidative stress (Guo et
al., 2010). Along these same lines, it has been discovered that
ATM is important in the generation of the anti-oxidant cofactor,
NADPH. NADPH is produced by the pentose phosphate cycle and
promotes the regeneration of GSH (reduced glutathione)(Rush et
al., 1985). ATM comes into play by phosphorylating heat shock
protein 27 (HSP27), which binds to and stimulates the activity
of glucose-6-phosphate dehydrogenase (G6PD), a key enzyme in the
pentose phosphate cycle (Cosentino et al., 2011). These
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oxidative stress functions of ATM are hypothesized to be one of
the causes of the neuronal degeneration witnessed in ataxia
telangiectasia patients. Neurons, one of the most active cell
types in the body, generate a large amount of oxidative,
metabolic byproducts. A lack of functional ATM means these
harmful byproducts are free to cause significant damage to the
cell, leading to apoptosis or necrosis.

Since the ATM gene was first identified in 1995, it has been the
subject of numerous studies approaching the molecule from
various angles. Currently, a PubMed search for “atm kinase”
returns almost 4,000 results. These reports all provide evidence
for ATM’s significant role in protecting the integrity of the
genome. However, recent studies have made clear that ATM’s role
in genetic protection does not begin and end with the DNA damage
response. As more work is done with this kinase, we will begin
to elucidate answers to questions we didn’t even know to ask.
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BRCA1

In 1994, researchers made a major breakthrough in uncovering the
cause of hereditary breast cancer by discovering the “breast and
ovarian cancer susceptibility gene 1”, now colloquially referred
to as BRCA1 (Miki et al., 1994). BRCA1 is a relatively large
protein, weighing approximately 220 kDa and spanning 1863 amino
acids. The N-terminus contains a RING finger domain, while the
C-terminus contains two BRCT domains. The intervening sequence
contains a nuclear export signal, two nuclear localization
signals (Chen et al., 1996), a DNA binding domain, as well as a
serine-glutamine (SQ) cluster domain (refer to Figure 2.3 for a
schematic of the BRCA1 protein, as well as important binding
partners).

BRCA1’s N-terminal RING domain is an E3 ubiquitin ligase and
forms a complex with another RING domain-containing protein,
BARD1 (Wu et al., 1996). This heterodimer has been shown to
autoubiquitinate BRCA1, which, in turn, increases BRCA1’s
ubiquitin ligase activity (Mallery et al., 2002; Nishikawa et
al., 2004; Wu-Baer et al., 2003). The BRCA1-BARD1 interaction
promotes nuclear localization by masking the BRCA1 nuclear
export signals, leaving the dual nuclear localization signals
uncovered (Fabbro et al., 2002; Rodriguez et al., 2004). BRCA1’s
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ubiquitin ligase activity is important for normal cellular
function, including the G2/M checkpoint and mitosis.

The SQ cluster domain is a region of serine and threonine
residues ranging from amino acids 1241-1530. These residues are
phosphorylated by ATM and ATR in response to DNA damage (among
other stimuli). ATM is the main kinase that phosphorylates BRCA1
in response to ionizing radiation (Cortez et al., 1999; Gatei et
al., 2000). ATR has redundant/backup phosphorylation duties
to/for ATM, and, as previously mentioned, is activated by
stimuli such as ultraviolet radiation and stalled replication
forks (Tibbetts et al., 2000). The redundant serine residues
that are phosphorylated by ATM and/or ATR are S1387, S1423,
S1457, and S1524. Serine 1387 is phosphorylated only by ATM (in
response to irradiation), while serine 1457 is uniquely
phosphorylated by ATR in response to ultraviolet radiation
(Gatei et al., 2001).

Many of these phosphorylations seem to have direct consequences
for cell cycle control. Serine 1387 phosphorylation is involved
in the intra-S checkpoint, whereas the phosphorylation of
serines 1423 and 1524 is important for G2/M checkpoint
activation (Xu et al., 2001, 2002). Additional phosphorylations
outside of the serine cluster domain are also important for
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checkpoint control. For example, Chk2 phosphorylates BRCA1 on
serine 988 in response to microtubule damage, inhibiting the
microtubule nucleation activity of BRCA1 and preventing the
proper transition to, and through, mitosis (Chabalier-Taste et
al., 2008). Additionally, Ouchi et al found that phosphorylation
of serine 308 by the Aurora-A kinase is necessary to
successfully traverse the G2/M checkpoint (Ouchi et al.,
2004)(discussed further in this chapter, as well as Chapter 5).

The BRCA1 BRCT domains bind phospho-proteins containing the
phospho-serine-X-X-phenylalanine (pSer-X-X-Phe) motif, where “X”
represents any amino acid (Manke et al., 2003; Yu et al., 2003).
The four most heavily studied BRCT binding partners of BRCA1 are
Abraxas, BACH1, CtIP, and PALB2 (Caestecker and Van de Walle,
2013; Wang et al., 2007; Yu and Chen, 2004). Abraxas bridges
another protein, RAP80, to BRCA1. This complex, along with the
BRCA1-BACH1 and BRCA1-CtIP complexes, have all been shown to be
involved in the homologous repair of DSBs (Litman et al., 2005;
Sartori et al., 2007; Yan et al., 2007). The BRCA1-Abraxas-RAP80
complex is important because RAP80 localizes BRCA1 to sites of
DSBs through its dual ubiquitin-interacting motifs, which are
attracted to polyubiquitinated H2AX (a post-translation
modification of H2AX mediated by MDC1 which occurs at sites of
DSBs) (Caestecker and Van de Walle, 2013; Sobhian et al., 2007).
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Additional work has demonstrated that BACH1, a helicase, is
involved in S-phase progression, and it has been shown that
mutations in BACH1 interferes with normal DSB repair, suggesting
that the BRCA1-BACH1 interaction is essential to BRCA1’s DNA
repair function (Cantor et al., 2001; Kumaraswamy and
Shiekhattar, 2007).

The final major BRCA1-BRCT interacting protein, CtIP, has been
shown to be important for BRCA1’s function in the G2/M
checkpoint. In 2004, it was found that the BRCA1-CtIP complex
only existed in the G2 phase of the cell cycle, and that this
interaction is necessary for the DNA damage-induced
phosphorylation of Chk1 and activation of the G2/M checkpoint
(Yu and Chen, 2004). Later, the same group demonstrated that
CtIP was ubiquitinated by BRCA1. This ubiquitination does not
signal CtIP for destruction, rather, it promotes CtIP’s
association with chromatin following DNA damage, and was also
found to be necessary for G2/M checkpoint activation (Yu et al.,
2006).

BRCA1’s role in cell cycle control goes far beyond its
interaction with CtIP. The BRCT domain has also been found to
function in transcription of the p21 promoter through its
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association with p53 (Chai et al., 1999; Li et al., 1999; Ouchi
et al., 1998; Zhang et al., 1998). After DNA damage, CtIP can
dissociate from BRCA1, allowing p53 to bind which leads to the
transcriptionally-mediated aspect of cell cycle control (as well
as DNA repair). Along these same lines, BRCA1 can also associate
with the acetyltransferase complex CBP/p300, which further
increases the BRCA1-p53 dependent transcriptional activity (Pao
et al., 2000). As p53 has been shown to be active in both the
G1/S and G2/M checkpoints (Agarwal et al., 1995), it is probable
that BRCA1 is also involved in both of these major checkpoints.

Another experimentally validated model for BRCA1’s function in
the cell cycle revolves around its regulation of centrosomes.
Centrosomes are cellular organelles that nucleate microtubules
throughout interphase and mitosis (Moritz et al., 1995).
Centrosomes duplicate once per cell cycle and, during mitosis,
move to opposite ends of the cell forming the bipolar mitotic
spindle (see (Morgan, 2007) for review). BRCA1, along with
BARD1, have been found to localize to the centrosome and ensure
that centrosomal duplication occurs only once per cell cycle, a
process which is important in preventing the formation of
multipolar mitotic spindles, unequal chromosome segregation, and
aneuploidy (Sankaran et al., 2005, 2006; Starita et al., 2004).
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In cells containing BRCA1 mutations, centrosomal amplification
and aneuploidy are commonly recorded events, leading to and
enhancing the neoplastic transformation of these cells (Deng,
2001; Schlegel et al., 2003; Starita et al., 2004; Xu et al.,
1999). The BRCA1-BARD1 complex ubiquitinates γ-tubulin, a
modification that regulates the initial nucleation of
microtubules at centrosomes (Sankaran et al., 2005). Microtubule
nucleation involves taking free tubulin dimers and assembling
them into a stable aggregate known as “nucleation centers”. The
most important nucleation center is known as the γ-tubulin ring
complex, or γ-TuRC. It is here where the BRCA1-BARD1 heterodimer
exerts its regulation, by ubiquitinating and prevening excessive
nucleation and spindle formation (Sankaran et al., 2007; Starita
et al., 2004).

Recent work has demonstrated that the protein

CRM1 (chromosome region maintenance 1) mediates the nuclear
export of BRCA1, as well as its localization to centrosomes
(Brodie and Henderson, 2012). This same report showed that
Aurora A’s binding and phosphorylation of BRCA1 was important
for its centrosomal retention (discussed further in Chapter 4).

BRCA1’s ubiquitin-mediated cell cycle control is not limited to
centrosomes. It was previously shown that in response to DNA
damage, BRCA1 was crucial to G2/M arrest by its downregulation
of Cyclin B/CDK1 and Cdc25C (Yarden et al., 2002, 2012).
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However, the mechanism by which this occured was unknown. In
late 2012, the Yarden lab demonstrated that this downregulation
was due to BRCA1’s E3 ubiquitin ligase activity. After DNA
damage (induced by either γ-irradiation or Neocarzinostatin),
the BRCA1-BARD1 complex polyubiquitinates both Cyclin B and
Cdc25C, which leads to their proteasomal degradation (Shabbeer
et al., 2012). Without these crucial proteins, the transition to
mitosis cannot occur.

BRCA1, much like ATM, clearly plays diverse and important roles
in the protection of cellular structure and function. While a
number of stimuli have been shown to cause distinct posttranslation modifications of BRCA1 (leading to downstream
effects), much investigation remains to be done to fully
elucidate all the mechanisms by which BRCA1 exerts its caretaker
functions. As it stands, BRCA1 appears to have widespread
influence over the life cycle of the cell.
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Aurora A kinase

Aurora A is a 48 kDa protein comprised of 403 amino acids, with
its important kinase domain spanning from amino acids 133-383.
It was first crystallized in 2002, and there are now at least 57
crystal structures of Aurora A in complexes with other proteins
or pharmacologic inhibitors (Nikonova et al., 2013).

In regards to the cellular life cycle, it has been well
documented that Aurora A functions in both centrosomal
regulation and the progression through mitosis. In S phase
(after centrosomal replication), Aurora A begins to accumulate
at the centrosomes, where it is responsible for recruiting a
number of proteins to the pericentrosomal material, such as γtubulin, centrosomin, LATS2, TACC, and NDEL1 (Abe et al., 2006;
Conte et al., 2003; Hannak et al., 2001; Mori et al., 2007; Toji
et al., 2004). These proteins, along with Aurora A, increase the
microtubule nucleation activity of the centrosomes.

The events responsible for Aurora A activation are not clearcut. Indeed, there are a multitude of different interactions and
phosphorylations which can influence Aurora A’s activity. The
earliest described (and most thoroughly studied) cofactor of
Aurora A activation is TPX2. TPX2 binds to Aurora A and helps
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target it to the mitotic spindles (Kufer et al., 2002). Once
TPX2 binds, the activation segment of Aurora A moves inside the
kinase’s catalytic pocket, inducing the autophosphorylation of
threonine 288 (Bayliss et al., 2003; Eyers et al., 2003). The
binding of TPX2 also protects Aurora A from the deactivating
functions of protein phosphatase 1 (PP1) by “hiding” the
threonine 288 residue from the enzymatic activity of PP1
(Bayliss et al., 2003; Eyers et al., 2003).

Two other important cofactors are Ajuba and Bora, to which
Aurora A binds and phosphorylates. Circuitously, Ajuba binding
is necessary for Aurora A autophosphorylation (which, in turn,
phosphorylates Ajuba) (Hirota et al., 2003). This activation
takes place at the centrosomes, and is crucial for the
activation of the Cyclin B/CDK1 complex. Similarly to Ajuba,
Bora binding and phosphorylation enhances Aurora A’s kinase
activity (Hutterer et al., 2006), though the exact function of
this interaction remains unclear. Studies in Drosophila
identified Bora as important for asymmetric cell division, which
would play into Aurora A’s role in regulating mitosis (Berdnik
and Knoblich, 2002).

There are several additional proteins which experimental data
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has demonstrated to be involved in Aurora A’s activation (see
(Nikonova et al., 2013) for a helpful summary). At present,
however, the literature is murky in regards to what exactly
these proteins are doing, and why. This likely stems from the
fact that several different model systems have been used to
study Aurora A (Xenopus, Drosophila, etc.) and not all
functions/interactions are conserved across species. The big
picture question involves solving how all these cofactors work
together to regulate Aurora A’s function.

Once activated, Aurora A is involved in several downstream
pathways (see Figure 2.4 for an overview of key Aurora A
functions). As previously stated, Aurora A (coupled with Bora)
is key in activating the Cyclin B/CDK1 complex. This complex is
initially gathered and activated at centrosomes, and Aurora A
positively reinforces this activation (Jackman et al., 2003; De
Souza et al., 2000). The hypothesized signaling pathway has an
activated Aurora A/Bora complex phosphorylating and activating
Plk1. Plk1, once activated, feeds into the loop of recruiting
more Aurora A to the centrosomes, where Aurora A can then
phosphorylate Cdc25B (Dutertre et al., 2004). Cdc25B is required
for the initial centrosomal activation of the Cyclin B/CDK1
complex (Lindqvist et al., 2005), providing a mechanism by which
Aurora A can directly push cells through the G2/M transition.
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Several studies have investigated the consequences of Aurora A
mutation/inhibition on centrosomal maturation and bipolar
spindle formation. Often, depletion of Aurora A leads to
monopolar spindle formation, preventing the accurate progression
through mitosis (Glover et al., 1995; Hannak et al., 2001; Liu
and Ruderman, 2006; Roghi et al., 1998). There are several
possible mechanisms by which this takes place. Aurora A has been
shown to phosphorylate Eg5, a kinesin which is involved in
centrosome separation (Giet et al., 1999). However, it is not
known if this phosphorylation is essential for Eg5’s activity.

Aurora A also targets and phosphorylates a protein called LIMK1.
As is the case with Eg5, LIMK1 is a proposed regulator of
bipolar spindle formation, but it is not known if Aurora A’s
phosphorylation is important for this function (Chakrabarti et
al., 2007; Ritchey et al., 2012). This phosphorylation is
important, however, for the mitotic co-localization of Aurora A
and LIMK1. Additionally, Aurora A is known to affect astral
microtubules, which connect centrosomes to the cell cortex and
can influence bipolar mitotic spindle formation (Giet et al.,
1999). Further work needs to be done in this area in order to
fully elucidate how Aurora A contributes to spindle formation,
and, in return, function (see (Nikonova et al., 2013) for
discussion).
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Finally, once Aurora A has completed its duties in shepherding
cells through mitosis, it needs to be degraded (unlike ATM and
BRCA1, which function throughout the cell cycle). This is done
though an E3 ubiquitin ligase named the Anaphase Promoting
Complex/Cyclosome (APC/C) (Vader and Lens, 2008). At the end of
mitosis, Aurora A is targeted for destruction, a mechanism by
which it is ensured that low levels of mitosis-promoting
proteins exist in G1. However, mutations in Aurora A (or other
proteins) can arise which prevent its destruction, enhance its
function, or alter key activities. When this occurs, malignancy
can result.

Aurora A has been shown to be mutated in a number of cancers
(see (Katayama et al., 2003), for example). However, isolated
mutations in Aurora A are not enough to induce malignancy (Zhou
et al., 1998), indicating that other oncogenic events must take
place before a cancerous Aurora A phenotype can arise (Tatsuka
et al., 2005). Aurora A is located on chromosome 20q13.2, a
region which is frequently amplified in solid tumors (Nikonova
et al., 2013). Typical features of pathologic Aurora A function
include amplified centrosomes, multipolar spindles, aneuploidy,
and deficient cell cycle checkpoints (Meraldi et al., 2002;
Nikonova et al., 2013).
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Aurora A’s neoplastic potential has been shown to depend on p53
status. Aurora A directly phosphorylates p53, and, like ATM and
BRCA1, stabilizes it, leading to downstream transcriptional
events (Katayama et al., 2004; Liu et al., 2004). In mouse
models, Aurora A was unable to produce tumors except in a p53knockout background (Fukasawa et al., 1996). This is presumed to
be caused by the aneuploid cells coming up against the p53mediated G1/S checkpoint which, when intact, activates and sends
cells into senescence/death (Fukasawa et al., 1996). While
Aurora A can activate p53 through phosphorylation, it can also
inhibit it. By phosphorylating Serine 315 of p53, Aurora A
increases the MDM2-dependent degradation of the protein
(Katayama et al., 2004). Conversely, p53 can bind to the
catalytic domain of Aurora A, inhibiting it (Chen et al., 2002;
Eyers et al., 2003).

Recently, this relationship was highlighted as a key factor in
maintaining stem cell pluripotency. Using a short hairpin (sh)
RNA screen, Lee et al found that depleting Aurora A resulted in
compromised self-renewal, leading to differentiation. They
discovered that loss of Aurora A leads to upregulated p53, a
finding which supports previous studies (i.e. (Katayama et al.,
2004). Phosphorylation of p53 by Aurora A also downregulated the
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p53-mediated suppression of iPS cell reprogramming (Lee et al.,
2012). Few other studies have been conducted on Aurora A and ES
cells. In conditional knockout mice, it was shown that
differential Aurora A expression can influence early mouse
embryo patterning (while complete knockout was found to be
embryonically lethal) (Yoon et al., 2012). Additionally, it was
also shown (again in mice) that Aurora A is crucial for
epidermal differentiation and development. Epidermal deficiency
of Aurora A was shown to promote aberrant mitosis, mitotic
slippage, and cell death (Torchia et al., 2013). Clearly, more
research is needed in this area to clarify what role Aurora A
plays in both pluripotent and somatic cells.
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Chapter 3:
Modulation of ATM function:
effects on the cell cycle
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Over the past fifteen years, the successful culture and
propagation of human embryonic stem cells has generated new hope
for the development of novel therapies based in regenerative
medicine. Unlike somatic cells, hESCs can be cultured in an
undifferentiated state for long periods, while retaining the
ability to form cells of all three embryonic germ layers
(Thomson et al., 1998). Unfortunately, therapies have been slow
to develop, as obstacles to expanding these cells ex vivo have
arisen.

One such obstacle is aneuploidy. Mouse, human, and induced
pluripotent stem cells fail to remain euploid after prolonged
culturing (Draper et al., 2004; Longo et al., 1997; Mayshar et
al., 2010). If aneuploid/genetically unstable hESCs are
transplanted, cancer can result (Amariglio et al., 2009).
Malignant transformation arises from cells acquiring errors in
their genome, resulting in a gain of function or loss of
regulation. To prevent these genomic flaws from inciting
unwarranted growth, cells have evolved methods to arrest the
cell cycle and repair the detected mistakes. If the DNA cannot
be repaired, cells undergo apoptosis, a small sacrifice to
preserve the larger organism. If cells fail to arrest and
apoptosis does not occur, cancer can develop, leading to loss of
function and, if left untreated, death.
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As hESCs display a shortened G1 phase (2.5 – 3 hours) and a
“leaky” G1/S checkpoint (Boheler, 2009; Nouspikel, 2013), there
is increased pressure on the G2/M checkpoint to detect any
genetic abnormalities and arrest the cell appropriately. Two
significant events will trigger a checkpoint at the mitotic
boundary: DNA damage and/or catenated chromatin (Downes et al.,
1994). The fact that DNA damage can produce genomic instability
is a well-known and well-studied process (see (Abbas et al.,
2013), for example. However, what role decatenation and the
decatenation checkpoint plays in retaining genetic fidelity is
much more poorly understood. If a cell fails to properly
decatenate its chromosomes, a cell cycle checkpoint (distinct
from the DNA damage checkpoint) activates, arresting cells at
the G2/M phase (Downes et al., 1994). If the checkpoint does not
activate, and cells complete division with catenated
chromosomes, nondisjunction and breakage can occur. This can
lead to translocations and other abnormalities in daughter
cells.

Previous work has described a deficient decatenation checkpoint
in mouse embryonic stem cells (Damelin et al., 2005), and
progress has been made towards characterizing the checkpoint’s
pathway. Recently, it has been posited that the DNA damage
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signaling protein ATM mediates the decatenation checkpoint
(Bower et al., 2010b), though the exact cascade remains unknown.
ATM’s potential involvement is significant because previous work
from our lab has demonstrated that ATM, while present in hESCs,
does not play its canonical role in double strand break repair
in pluripotent cells (Adams et al., 2010a). This finding has
been supported by other labs (see (Nagaria et al., 2013) for
review).

The purpose of this study is to clarify what role ATM plays in
hESCs. A previous report demonstrated that ATM is activated in
response to DNA damage in hESCs, and that cells arrest in G2
(Momcilović et al., 2009). These researchers then went on to
show, using the ATM specific inhibitor KU-55933, that this
arrest could be abrogated. However, Momcilovic et al drew these
conclusions using an immense dose of KU-55933 (100 μM, 10x the
concentration normally used), a dose that could conceivably
affect several other proteins involved in the DNA damage
response.

Herein, we will investigate the role of ATM in cell cycle
control using the next-generation ATM inhibitor, KU-60019. We
have demonstrated KU-60019 to be a highly potent, highly
specific inhibitor of ATM (Golding et al., 2009). We
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successfully demonstrate that, in hESCs, ATM is activated in
response to DNA damage as well as the inhibition of
decatenation. Both of these insults cause a G2/M arrest, and
this arrest is abrogated by the inhibition of ATM, supporting
the hypothesis that ATM mediates the G2/M checkpoint.
Additionally, we show, using live cell imaging, that inhibiting
ATM significantly increases the time it takes for cells to
complete mitosis. When decatenation is inhibited concurrently
with ATM, cells will enter mitosis and fail to separate,
essentially “giving up” and re-entering the cell cycle with
double the normal amount of DNA. Following up on this finding,
we show that prolonged culture under ATM inhibition causes an
increase in DNA content, and that wash out and culture of cells
in normal media begins to reverse this effect.
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Materials and Methods

Antibodies, reagents, and irradiation:
Antibodies used were anti-p-ATM (1:1000) (Cell Signaling), -ATM
(1:1000) (GeneTex, Inc.), -DNA-PK (1:1000) (BD Pharmingen), -pHistone H3 (1:500) (Cell Signaling Technologies), -CREST (1:75)
(Fitzgerald Industries), and -Cyclin A (1:50) (Santa Cruz
Biotechnologies). KU-60019 (provided by KuDOS Pharmaceuticals,
Inc.) was dissolved in DMSO and used at a concentration of 3 μM.
ICRF-193 (Enzo Life Sciences) was dissolved in DMSO and used at
a concentration of 10 μM. Colcemid (Sigma-Aldrich) and
nocodazole (Sigma-Aldrich) were dissolved in DMSO and used at
concentrations of 100 ng and 100 nM, respectively. Irradiations
were performed using a MDS Nordion Gammacell 40 research
irradiator with a Cs-137 source delivering an approximate dose
of 1.05 Gy/min.

Cell culture:
The human ESCs BG01V (ATCC, Rockville, MD), H9 (Thomson et al.,
1998), and H9-(v)1 (Werbowetski-Ogilvie et al., 2009) were
cultured on a feeder-free

system using a Matrigel™ (BD

Biosciences) basement membrane substrate and mTeSR™ (STEMCELL
Technologies) or Stemline™ (Sigma-Aldrich) media. Matrigel™
coated dishes were created using WiCell™ protocols. The media
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was changed daily and cells were passaged with Dispase™
(STEMCELL Technologies) at least once every five days.
Experiments were performed 24-48 hours after passaging.

Western blotting:
Western blotting was performed as previously described (Adams et
al., 2010a) with additional modifications. Cells were lysed in
RIPA buffer supplemented with HALT™ protease and phosphatase
inhibitors (Sigma-Aldrich). Proteins were separated on
Criterion™ TGX gels (Bio-Rad Laboratories) and transferred to
PVDF membranes, which were exposed to primary antibodies at a
1:1000 dilution. Protein bands were detected and quantified
using infrared-emitting conjugated secondary antibodies, either
anti-rabbit DyeLight 800 (Rockland Immunochemicals,
Gilbertsville PA) or anti-mouse Alexa 680 (Invitrogen) using the
Odyssey infrared imaging system from Li-Cor Biosciences
(Lincoln, NE). Densitometry was performed using ImageJ or Image
Studio v2.0.

Metaphase spreads and pseudomitotic index:
Acquisition of metaphase spreads was accomplished as previously
described (Campos et al., 2009). Cells and culture media were
collected and centrifuged. The resulting pellet was resuspended
in a hypotonic potassium chloride solution. The preparation was
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fixed in a freshly made 3:1 methanol:acetic acid solution and
dropped onto glass slides. The slides were dried over a steam
bath and stained with Giemsa (Sigma-Aldrich). They were then
imaged using the Ariol automated image analysis system
(Molecular Devices LTD). Nuclei and metaphase spreads were
counted using ImageJ. The percentage of entangled chromosomes
(“pseudomitoses”) in ICRF-193 cells were divided by the
percentage of metaphase spreads in cells treated with colcemid
alone, giving the pseudomitotic index (Damelin et al., 2005).

Flow cytometry:
Cells were fixed in 100% methanol, permeabilized in 1% Triton X100/casein, and incubated with anti–phospho-Histone H3 antibody
at 1:500 dilution for 1 h 30 min at room temperature. Cells were
washed in PBS and incubated with goat anti-rabbit Alexa Fluor
488 at 1:500 dilution for 45 min at room temperature. Cell cycle
distribution was analyzed by propidium iodide staining (5 Ag/mL,
0.1% Triton X-100/PBS). Flow cytometry was done on a BD
Biosciences FACS Canto flow cytometer at the VCU Flow Cytometry
Core Facility. Data was analyzed using the FACSDiva software.
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Confocal imaging:
Confocal imaging was performed as described previously (Adams et
al., 2010a) with additional modifications. Cells were grown on
Lab-Tek (Naperville, IL) glass slides coated with Matrigel.
After treatment, cells were fixed with 3% paraformaldehyde,
permeabilized with 0.5% Triton-X 100 in phosphate-buffered
saline (PBS) and blocked with casein/3% goat serum. Primary
antibodies were incubated overnight at 4 degrees, with rotation
(using the concentrations listed previously). The next day,
samples were incubated for 2.5 hours at room temperature with a
secondary antibodies solution (Alexa 488 goat anti-rabbit or
goat anti-mouse 546 Fab fragment (Invitrogen)) at a 1:400
dilution. The nuclei were counterstained with DAPI (1 mg/ml).
Cells were imaged using a Zeiss LSM 710 Meta imaging system in
the VCU Microscopy Facility and analyzed using the Volocity
software from PerkinElmer.

Live-cell imaging:
Live-cell imaging was performed as described in (Beckta et al.,
2012), using a Zeiss Cell Observer SD spinning disk confocal
microscope. BG01V hESCs were transduced with a Histone H2BmCherry construct to visualize chromatin. Glass-bottom dishes
were coated with Matrigel and cells were passaged onto these
dishes 24-48 hours prior to recording. Cells were kept on an
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incubated stage at 37°C and 5% CO2. Videos were analyzed using
PerkinElmer’s Volocity software.

Statistics:
ANOVA, t-tests, and linear regression were performed using
GraphPad Prism 3.0 (GraphPad Software, Inc). P values are
indicated as *, 0.05, **, 0.01, and ***, 0.001.
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Results

ATM is present and active in hESCs. KU-60019 inhibits ATM
activation in response to irradiation.

Studies were conducted using the BG01V, H9, and H9 variant H9(v)1 hESC lines. Our lab has previously developed optimal
conditions for the growth and propagation of hESCs (Adams et
al., 2010a). Notably, we employ a basement membrane substrate to
grow the hESCs, thus avoiding the use of MEF feeder layers and
ensuring our cultures are free of xenobiotic contamination.
Successful maintenance of the pluripotent state was verified by
immunocytochemistry (ICC) for SSEA-4 (Figure 3.1). Western
blotting was used to confirm that ATM was present and active in
the hESCs, and that KU-60019, a drug which we have shown to be a
highly effective inhibitor of ATM (Golding et al., 2009),
functioned as expected at a concentration which we have
determined only inhibits ATM. hESCs were exposed to 3 μM of KU60019, 2 Gy of radiation, or both KU-60019 and radiation. KU60019 was added 30 minutes before irradiation; cells were
harvested 30 minutes after irradiation. Predictably, irradiation
catalyzed the activation of ATM, and KU-60019 abrogated this
effect (Figure 3.2).
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Catalytic inhibition of Topoisomerase II activates ATM and
accumulates cells in G2. KU-60019 inhibits ATM activation.

During and after DNA replication, daughter chromatids contain
areas of entanglement, or catenations. The ability of cells to
resolve these entanglements is dependent upon topoisomerase II
(topoII), which unravels the chromosomes via the same method it
uses to relieve helical stress. In order to inhibit
decatenation, we used the bisdioxopiperazine ICRF-193, a topoII
catalytic inhibitor that does not cause DNA double strand breaks
(Roca et al., 1994). Treatment with 10 μM of ICRF-193 for four
hours caused significant ATM activation in S and G2 phase,
though this activation occurred most significantly in G2 (Figure
3). Exposure to KU-60019 in addition to ICRF-193 inhibited ATM
activation (Figure 3.3). Cell cycle analysis revealed that in
contrast to control or KU-treated cells, exposure to ICRF-193
accumulated cells in G2 (Figure 3.4). These data indicate that
after catalytic inhibition of topoisomerase II, hESCs activate
ATM and enact the decatenation checkpoint.
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Inhibition of ATM abrogates both the DNA damage and the
decatenation checkpoints.

The purpose of a G2 arrest is to prevent damaged cells from
entering mitosis and passing on any deleterious genetic lesions
to daughter cells. Thus, we determined the mitotic accumulation
of hESCs after inhibition of decatenation to assess the
effectiveness of the G2/M checkpoint. To ensure that we are
looking exclusively at G2/M entry (and prevent any confounding
results from differences in mitotic exit) we used colcemid, a
microtubule poison that prevents mitotic exit (Bower et al.,
2010b). H9, H9-v1, and BG01V cells were treated for four hours
with KU-60019, ICRF-193, or both KU-60019 and ICRF-193, and
analyzed for positive staining of phospho-Histone H3 (an
established marker of mitosis). Catalytic inhibition of TopoII
significantly reduced mitotic accumulation; inhibition of ATM
abolished this effect (Figures 3.5A, 3.5B, 3.5C). This result
was also observed in hESCs treated with irradiation (Figure
3.6A).
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Inhibition of ATM abrogates the decatenation checkpoint and
increases the mitotic entry rate.

In order to calculate the mitotic entry rate of hESCs, H9 cells
were exposed to ICRF-193 and/or KU-60019 for 2, 4, and 6 hours.
ICRF-193 reduced the mitotic accumulation and rate of
accumulation, decreasing the slope (from colcemid-only control)
by 2.7 fold. When KU-60019 was added simultaneously with ICRF193, mitotic accumulation recovered, and the mitotic entry rate
rose dramatically, increasing the slope nearly 2 fold (Figure
3.7A). BG01V hESCs were exposed to the same treatments. Similar
to the H9 cells, ICRF-193 reduced the mitotic accumulation and
rate of accumulation (decreasing the slope 1.5 fold). When KU60019 was added simultaneously with ICRF-193, mitotic
accumulation recovered, and the mitotic entry rate increased
(increasing the slope 1.3 fold) (Figure 3.7B).

Inhibition of ATM significantly decreases the efficiency of the
decatenation checkpoint.

To determine the efficiency of the checkpoint, we used metaphase
spreads and calculated the pseudomitotic index, which is defined
as “the frequency of pseudomitosis in ICRF-193-treated cells
divided by the frequency of mitosis in mock-treated cells”
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(Damelin et al., 2005).

“Pseudomitosis” refers to the

appearance of chromosomes in mitotic spreads that have a
bizarre, entangled morphology (Figure 3.8A). As seen in Figure
3.8B, we found that BG01V hES cells have a baseline
pseudomitotic index of ~30%. Inhibiting ATM significantly
increased the pseudomitotic index 4-fold. In addition to
demonstrating ATM’s importance in preventing cells from entering
mitosis with tangled DNA, these results also support a previous
study’s finding that pluripotent cells have a deficient
decatenation checkpoint, as fully differentiated cells have a
pseudomitotic index of ~1% (Damelin et al., 2005).

Inhibition of ATM increases the time it takes to complete the
stages of mitosis.

As described in (Beckta et al., 2012), live-cell imaging studies
were conducted on BG01V cells transduced with a Histone H2BmCherry construct. The Wahl lab has demonstrated that the H2Bfluorescent fusion protein is incorporated into nucleosomes,
does not affect cell cycle progression, and permits high
resolution confocal imaging of interphase chromatin and mitotic
chromosomes (Kanda et al., 1998).

As our previous data demonstrates, ATM is necessary for cells to
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detect genetic abnormalities and prevent further cell cycle
progression. We were therefore interested in investigating if
inhibiting ATM prolonged the time of mitosis, with the rationale
being that catenations/DNA damage would escape notice and cells
would erroneously enter mitosis, “discovering” and attempting to
resolve any genomic lesions while concurrently attempting to
divide. As hypothesized, inhibition of ATM prolonged the time of
mitosis. Addition of KU-60019 prolonged the prometaphase-tometaphase time by 28% (Figure 3.9A), the metaphase-to-chromatin
decondensation time by 17% (Figure 3.9B), and the overall time
of mitosis by 21% (Figure 3.9C). This data demonstrates that
without functional ATM, cells are still able to complete
mitosis, but the increased time it takes them to do so indicates
that they are either attempting to resolve undetected glitches
in their DNA or proceeding to divide with these genetic flaws
intact.

Inhibition of ATM causes tetraploid cell formation.

Our previous data has demonstrated the inhibiting both TopoII
and ATM allows catenated cells to enter mitosis. However, the
techniques used did not allow us to discern if the cells
remained viable. BG01V Histone H2B-mCherry cells were exposed to
various treatments and monitored via live-cell imaging for
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several hours. Under normal conditions, BG01V cells enter
mitosis at a rate of approximately 3.5% per hour (as calculated
by cells demonstrating prometaphase morphology divided by the
total number of cells observed). Addition of ICRF-193 reduces
the mitotic entry rate by ~3 fold (Figure 3.10A); supporting our
previous results which indicate that while exposure to ICRF-193
activates the decatenation checkpoint, this activation does not
result in complete arrest. While the majority of cells remained
in interphase, approximately 40% of the ICRF-193 treated cells
that entered mitosis “gave up” at metaphase, decondensed their
chromatin, and re-entered the cell cycle as newly minted
tetraploid cells (also known as “endoreduplication”) (Figure
3.10B). Cells were also exposed to both ICRF-193 and KU-60019,
which rescued mitotic entry to near control levels (Figure
3.10A). As was seen in the ICRF-193-only treated cells,
concurrent inhibition of ATM and decatenation caused nearly 40%
of mitotic cells to become tetraploid, however, the dramatically
increased mitotic entry rate meant that many more cells wound up
with a gain of DNA (Figure 10B). This data clearly demonstrates
the critical role ATM plays in preventing cells with gross
changes to their DNA content from dividing.
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Inhibition of ATM causes aneuploidy.

The previous data indicated that cells with enormous genomic
errors could survive and propagate if ATM was inhibited. We were
therefore interested in uncovering what changes prolonged
pharmacologic inhibition of ATM would cause in hESCs. H9 cells
were exposed to KU-60019 for 24 hours, fixed immediately, and
stained for CREST and Cyclin A. Kinetochores (revealed via CREST
staining) were compared between control and KU-60019 treated
cells. Cyclin A positive cells (representing S and G2 phase
cells) were excluded in the analysis. 24 hours of ATM inhibition
significantly increased the number of kinetochores counted per
cell (Figure 3.11A), indicating that these cells gained DNA.
Additionally, H9 cells were exposed to KU-60019 for 24 hours,
then media was replaced and cells were allowed to grow for 24
hours with no treatment, after which time the cells were fixed
and stained with CREST and Cyclin A. While there was still a
significant increase in the number of kinetochores per cell
after ATM inhibition, the 24 hour washout period allowed cells
to trend back to control levels (Figure 3.11B), suggesting that
once ATM inhibition is relieved aneuploid cells are removed from
the population (either via apoptosis or necrosis).
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Chapter Summary

Crucial to the development of therapeutics based on hESCs is an
understanding of how they maintain genomic stability. Previous
work in our lab has shown that while ATM is present and active
in hESCs, it is not performing its canonical role in the DNA
damage response. However, ATM is a key part of innumerable
cellular signaling pathways that are important in the
maintenance of genomic integrity. In order to elucidate ATM’s
role in hESCs, we turned our attention to the G2/M decatenation
and DNA damage checkpoints. Our current understanding of hESC
cell cycle regulation suggests that these cells spend a very
short time in G1 and lack a stringent G1/S checkpoint. This
makes the enforcement of a G2/M checkpoint tremendously critical
in hESCs. In this chapter, I have demonstrated that ATM is
crucial for enacting the G2/M checkpoint(s) and preventing the
generation of aneuploid cells.

The data presented here shows that catalytic inhibition of
TopoII activates ATM and causes cells to arrest in G2. While
there is disparity in the literature, the activation of ATM in
response to decatenation inhibition is consistent with other
reports. Our studies used the highly effective ATM inhibitor,
KU-60019. Our lab has previously shown KU-60019 to be
105

significantly more effective than KU-55933, the drug used in the
only other study examining ATM’s role in hESC G2/M arrest
(Momcilović et al., 2009). As seen in Figures 2 and 3, KU-60019
is able to block the activation of ATM in hESCs at a dose of 3
μM. However, there appears to be residual levels of p-ATM still
present even after KU treatment. This is a phenomenon we have
encountered before, and it has been shown that p-S1981 ATM
antibody we use has the capacity to recognize multiple
substrates (Matsuoka et al., 2007a). The background levels
represent other activated members of the DNA damage response,
either due to the ICRF-193 treatment or other cellular
activities.

We turned to live-cell imaging to record what is happening with
ATM inhibition on a cell-by-cell basis. A previous report has
shown that certain stages of mitosis were prolonged in MEFs with
both ATM and p21 knocked out (Shen et al., 2005). This is of
interest to our studies, as hESCs have low levels of p21 (see
Chapter 1), so the results obtained with the use of an ATM
inhibitor in a p21-negative background should be similar.
However, these generalizations are hard to make. First, as with
the other reports investigating ATM’s role in cell cycle
regulation, there are significant species and lineage
differences between stem cell populations. MEFs are both non106

human and lack pluripotency. Additionally, use of cells with
permanently knocked out proteins can encourage the cell to adapt
and use other proteins/pathways. Here, we show for the first
time that transient inhibition of ATM in hESCs is enough to
significantly perturb the progression through mitosis. We
hypothesize that this is potentially due to two reasons: first,
ATM inhibition renders the cell unable to sense genomic insults
and resolve them before entering mitosis. The cell must then
deal with these issues as they interfere with the process of
mitosis. Second, a recent manuscript has been published showing
that ATM is important for the progression through mitosis via
its signaling activity at the spindle assembly checkpoint (Yang
et al., 2011). While this study was not done in pluripotent
cells, ATM could potentially be playing a similar role in hESCs,
causing an increase in the time of mitosis.

Finally, we demonstrate that inhibiting ATM for as little as 24
hours causes a significant increase in kinetochore staining,
indicating a gain of DNA content. When cells were allowed to
have a 24-hour washout period, kinetochore staining was still
significantly increased, but trending back towards control
levels. This suggests that the aneuploid cells, once ATM
inhibition was released, undergo some type of cell death. Of
note, the control groups only averaged around 19 kinetochores
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per cell, instead of the expected 46. This is likely to be
caused by the spatial relationships of the kinetochores in the
nucleus. If CREST antigens are too close together (either in the
X/Y or Z planes) then these foci will merge together and appear
as one, larger foci. It would be virtually impossible to tease
these groupings out using confocal imaging. Future studies using
assays such as fluorescent in situ hybridization (FISH) could be
employed to obtain a more accurate measurement of changes in DNA
content.

In summary, the experiments presented in this chapter have shown
that ATM is important for G2/M cell cycle arrest, either due to
DNA damage or inhibition of decatenation, in hESCs. At the same
time, these experiments show that hESCs have a relatively weak
decatenation checkpoint. Live-cell imaging studies have revealed
that inhibition of ATM allows cells with substantially tangled
DNA to attempt mitosis, and, when that attempt fails, to resume
cycling as tetraploid cells. Importantly, experimental results
have directly demonstrated that prolonged inhibition of ATM
causes aneuploidy, and release from ATM inhibition reduces this
effect. Taken together, these observations establish the
importance of ATM in maintaining the genomic stability of hESCs.
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Chapter 4:
ATM, BRCA1, and Aurora A: How to
Arrest a Cell
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Introduction

The mechanisms by which ATM could enact a G2/M arrest are
numerous. A large-scale substrate analysis has identified more
than 700 possible (and confirmed) targets of ATM (Matsuoka et
al., 2007b), and, as is the case when studying globally-acting
proteins, many of these targets play some sort of role in cell
cycle regulation. Some of the early research into the
decatenation checkpoint found evidence that the protein Plk1
(polo-like kinase 1) is involved in checkpoint activation (Luo
et al., 2009), and other studies have found that Plk1 is
regulated by ATM in response to DNA damage (see (van Vugt et
al., 2001), for example). Additionally, as Plk1 is regulated
upstream by Aurora A, we decided to start the search for a
mechanism in the Aurora A/Plk1 signaling pathway.

Through exploring the literature for possible intersections
between ATM and G2/M regulation pathways, we uncovered a littlestudied interaction between BRCA1 (a well-described target of
ATM) and Aurora A. In 2004, a group working out of the Mt. Sinai
School of Medicine published a report in which they present
evidence showing that Aurora A binds to and phosphorylates
BRCA1, and that this interaction is important for promoting the
G2/M transition (Ouchi et al., 2004). Importantly, they showed
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that Aurora A binds to BRCA1 in the amino acid region 1314-1863,
which spans the SQ cluster domain where ATM exerts its kinase
activity. By creating a mutant version of BRCA1 that was nonphosphorylatable by Aurora A (S308N mutation), Ouchi and
colleagues found that these cells were unable to enter mitosis,
indicating that this small post translational modification of
BRCA1 had major cell cycle consequences.

Subsequent studies from the Parvin laboratory found that the
phosphorylation of BRCA1 by Aurora A inhibited BRCA1’s E3
ubiquitin ligase activity (Sankaran et al., 2005). BRCA1
functions at centrosomes to 1) prevent centrosome amplification
and 2) prevent microtubule nucleation. This second function, the
inhibition of microtubule nucleation, is a conundrum. BRCA1
localization to the centrosomes peaks during M phase, when
microtubule nucleation activity is highest (Sankaran et al.,
2005). How is this seemingly contradictory information
rectified? Sankaran et al found that Aurora A, by binding to and
phosphorylating BRCA1, inhibits the ubiquitin-mediated
inhibition, thus allowing appropriate formation of microtubules
(Sankaran et al., 2005). It appears likely that BRCA1 targets
centrosomes initially during S phase to prevent overamplification, and remains there in M phase, phosphorylated and
inactive, except in the case of DNA damage. An independent
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laboratory found that functional BRCA1 and Aurora A was
necessary to prevent centrosome over-amplification after DNA
damage (Brodie and Henderson, 2012). These studies suggest that
BRCA1 remains localized to centrosomes as a fail-safe in the
event that DNA damage is experienced and cycling needs to be
halted.

As activated ATM phosphorylates BRCA1 at several serine residues
in the amino acid region in which Aurora A binds, and Aurora A
binding/phosphorylation is necessary to inhibit BRCA1’s
inhibition of microtubules (allowing the transition into
mitosis), we hypothesize that ATM’s phosphorylation of BRCA1
disrupts Aurora A binding. This disruption means that BRCA1
continues to inhibit microtubules, and provides one plausible
mechanism by which ATM activation turns on the G2/M checkpoint
in response to DNA damage and/or tangled chromosomes.
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Materials and Methods

Antibodies, reagents, and irradiation:
Antibodies used were anti-Aurora A (1:1000 WB, 1:500 ICC) (Cell
Signaling Technologies), -p-Aurora A (1:1000 WB, 1:500 ICC)
(Cell Signaling Technologies), -BRCA1 (Ab-1, Ab-4) (1:1000 WB,
1:100 ICC) (Calbiochem), BRCA1 (C-20) (2 μg IP) (Santa Cruz
Biotechnologies), –p-S1423-BRCA1 (1:1000 WB, 1:500 ICC) (Santa
Cruz Biotechnologies), and –p-S308-BRCA1 (1:1000 WB) (kindly
provided by Toru Ouchi). KU-60019 (provided by KuDOS
Pharmaceuticals, Inc.) was dissolved in DMSO and used at a
concentration of 3 μM. Nocodazole (Sigma-Aldrich) was dissolved
in DMSO and used at a concentration of 100 nM. Irradiations were
performed using a MDS Nordion Gammacell 40 research irradiator
with a Cs-137 source delivering an approximate dose of 1.05
Gy/min.

Cell culture:
The hESCs BG01V (ATCC, Rockville, MD) and H9 (Thomson et al.,
1998) were maintained as described in Chapter 3. Experiments
were performed 24-48 hours after passaging, except in the case
of immunoprecipitation reactions, where experiments were
performed once cells became nearly confluent in a 10cm dish
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(totaling 0.75 - 1 milligrams of protein).

Western blotting:
Western blotting was performed as described in Chapter 3.

Confocal imaging:
Confocal imaging was performed as described in Chapter 3. For
co-localization experiments depicting cells in prometaphase,
hESCs were fixed and assayed after 4 hours of nocodazole
treatment. hESCs assayed for mitotic index were also fixed after
4 hours of nocodazole treatment.

Transfection:
Generation of wild-type BRCA1 plasmid:
pcDNA3(BssHII)-HA-3XFLAG-BRCA1 wild-type was generated as
described in (Dever et al., 2011).
Generation of 4P BRCA1 mutant plasmid:
First, plasmid pcDNA3 (BssHII)-HA-3XFLAG-BRCA1 S1387/1423A was
generated from plasmid pcDNA3-HA-BRCA1 S1387/1423A (kindly
provided by Bo Xu) by swapping the BamHI XhoI fragments with
pcDNA3 (BssHII)-HA-3XFLAG-BRCA1 wild-type.

The

S1387/1423/1457/1524A quadruple mutant was then generated from
plasmid pcDNA3(BssHII)-HA-3XFLAG-BRCA1 S1387/1423A by sequential
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rounds of QuikChange site-directed mutagenesis (Stratagene)
using primers GCAGTATTAACTGCACAGAAAAGTAGTG and
CACTACTTTTCTGTGCAGTTAATACTGC to create the S1457A mutation and
primers GAATAGAAACTACCCAGCTCAAGAGGAGCTC and
GAGCTCCTCTTGAGCTGGGTAGTTTCTATTC to create the S1524A mutation.

Transfection procedure:
Transfections were performed using Qiagen’s SuperFect and their
recommended protocol. In brief, 10 μg of plasmid DNA (in 5 μL of
water) was complexed with 10 μL of SuperFect. DNA/SuperFect
complex was incubated with cells for 3 hours, after which the
cells were washed 1x in PBS. Assays were conducted ~48 hours
after transfection.

Immunoprecipitation and co-immunoprecipitation:
Cells were lysed in a modified RIPA buffer (1% NP-40, 150 mM
NaCl, 50 mM HEPES, HALT™ protease and phosphatase) or MPER
buffer (Thermo Scientific Pierce). Protein levels were measured
to be ~750 μg. For BRCA1 immunoprecipitation, 5 μg of BRCA1 C-20
antibody was added to each lysate, and the samples were allowed
to incubate overnight at 4°. For p-BRCA1/Aurora A coimmunoprecipitation, 5 μg of p-S1423-BRCA1 was used. 50 μL of
Dynabeads (Invitrogen) were added the following morning and
incubated for an additional 2 hours at 4°. The samples were
115

washed three times in ice-cold PBS, mixed with Laemlli buffer +
β-mercaptoethanol, and boiled for 10 minutes. The lysates were
then loaded onto a Criterion™ TGX gel and run as earlier
described. To minimize noise from the IgG heavy chain, blots
were incubated with light chain specific secondary antibodies
(Jackson Immuno) at 1:600 and developed on a GelDoc (Bio-Rad
Laboratories) imaging system.

λ-phosphatase assay:
Lysates were immunoprecipitated as previously described using
the BRCA1 C-20 antibody. Lambda Protein Phosphatase (New England
BioLabs) was used per manufacturer’s protocols. In brief,
samples were incubated with ~1,200 units of λ-phosphatase for 1
hour at 30 °, after which time laemmli buffer was added and
samples were boiled for 10 minutes.

Statistics:
T-test was performed using GraphPad Prism 3.0 (GraphPad
Software, Inc). P value is indicated as ***, 0.001.

116

Results

ATM phosphorylates BRCA1 in response to DNA damage.

As discussed in Chapter 2, ATM directly phosphorylates BRCA1 in
the SQ domain in response to DNA damage. While this has been
demonstrated in multiple studies since it was first discovered,
no one has examined if this phenomenon occurs in hESCs. First,
hESCs were treated with or without KU-60019 for 30 minutes prior
to exposure to 5 Gy IR. Cells were allowed to incubate for 1
hour before lysates were harvested for western blot analysis. As
seen in Figure 4.1A, there is a high basal level of p-S1423BRCA1 in control and KU-60019-alone treated cells. Treatment
with IR caused a 1.6-fold increase in p-BRCA1 levels, while
concurrent treatment with KU-60019 prevented this increase.
These results indicate (in line with the literature) that ATM
phosphorylates BRCA1 in response to DNA damage in hESCs.

Unexpectedly, these results indicate that hESCs contain a high
endogenous level of p-BRCA1, even in the absence of any overt
DNA-damaging treatment. Additionally, inhibition of ATM, while
preventing the increase in p-BRCA1 levels, does not do much to
alleviate this phosphorylation (see Figure 4.1A, untreated vs.
KU-60019 treated lanes). These results could indicate two
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distinct possibilities: 1) the p-S1423-BRCA1 antibody used is
recognizing un-phosphorylated BRCA1, or, 2) hESCs, for whatever
reason, function with an unanticipatedly high amount of p-BRCA1.
The original manuscripts describing ATM’s phosphorylation of
BRCA1 used gel-shift assays to determine how these two proteins
interact (in lieu of having p-BRCA1-specific antibodies).
Therefore, to clarify which of the two possible events is
occurring here, endogenous BRCA1 was immunoprecipitated from
hESC lysates treated with or without IR and/or KU-60019. Samples
were then run out on a 7.5% gel for an extended period of time
to separate different molecular weight versions of BRCA1. As
seen in Figure 4.1B, control and KU-60019-treated cells stain
for two distinct versions of BRCA1. When treated with IR, a
third species develops, which disappears with concurrent ATM
inhibition. It appears that hESCs have three “versions” of
BRCA1, with varying amounts of post-translational modifications.
There appears to be a relatively constant amount of the highestmobility BRCA1 version throughout all groups. The middle-weight
band varies based on treatment, remaining fairly similar between
control and KU-60019-treated cells, while diminishing with
exposure to IR. It seems that the third, most heavily modified
band is generated using the middle-weight band as a substrate.
While it is presumed that the ATM-mediated post-translation
modification of BRCA1 is chiefly phosphorylation, this is not
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guaranteed. Therefore, hESCs were treated with or without IR,
harvested, and immunoprecipated for endogenous BRCA1. Extracts
were then exposed to λ-phosphatase, a Mn2+-dependent protein
phosphatase which removes phosphorylations from serine,
threonine, and tyrosine residues. As seen in Figure 4.1C,
exposure to IR induces the appearance of three different BRCA1
species, while λ-phosphatase treatment reverses this effect.
Collectively, these results indicate that BRCA1 is extensively
phosphorylated by ATM in response to DNA damage, and ATM
inhibition prevents this phosphorylation. However, it appears
that at least one other kinase (possibly ATR (Gatei et al.,
2001)) is still acting extensively in BRCA1’s SQ cluster domain,
regardless of treatment. Which protein is responsible and what
purpose this continuous phosphorylation serves remains unclear.

BRCA1 and Aurora A co-localize during mitosis.

Previous reports have indicated that BRCA1 interacts with Aurora
A, and that this interaction is important for the entry into
mitosis (Ouchi et al., 2004). To investigate if this occurs in
hESCs, cells were grown on chamber slides, fixed, and stained
for BRCA1 and p-Aurora A. Figure 4.2A shows BRCA1 and Aurora A
co-localize in prometaphase, while Figure 4.2B demonstrates this
interaction in metaphase. This co-localization was not witnessed
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in any other phase of the cell cycle, in fact, little to no
Aurora A staining (either total or phospho) was recorded outside
of mitosis. This is likely because Aurora A is expressed at low
levels during interphase, peaks at G2/M, and is degraded at the
end of mitosis (Tanaka et al., 2002; Vader and Lens, 2008).

Activation of ATM blocks the interaction of BRCA1 and Aurora A.
Treatment with KU-60019 reverses this effect.

Previous work has yielded data that shows Aurora A binding to
the region of BRCA1 in which the SQ cluster domain resides, and
that this binding is necessary for the S308-BRCA1
phosphorylation which promotes the transition into mitosis
(Ouchi et al., 2004). We hypothesized that activated ATM
phosphorylates BRCA1’s SQ cluster domain and disrupts this
interaction, and that this disruption is one mechanism by which
ATM arrests cells at the G2/M border. However, repeated attempts
at co-immunoprecipitating Aurora A with endogenous BRCA1 were
unsuccessful, regardless of treatment (a similar amount of
Aurora A always came down with BRCA1) (data not shown). Since
hESCs seem to contain high levels of p-BRCA1 (Figure 4.1), we
decided to use the p-S1423-BRCA1 antibody for both
immunocytochemistry co-localization and western blot coimmunoprecipitation experiments. Figure 4.3A shows p-BRCA1 co122
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localizing with Aurora A in control and KU-60019 treated cells.
In IR-treated cells, this interaction disappears, although most
nuclei demonstrated p-BRCA1 foci (presumably indicating areas of
DNA damage). When cells were irradiated under ATM inhibition,
the BRCA1/Aurora A co-localization was restored.

The same trend was seen with endogenous p-BRCA1 coimmunoprecipitation experiments. As demonstrated in Figure 4.3B,
a similar amount of Aurora A was immunoprecipitated along with
p-BRCA1 in control and KU-60019-treated lysates (1x and 1.3x,
respectively, when normalized for total amount of p-BRCA1).
Treatment with 5 Gy IR dramatically reduced the amount of Aurora
A pulled down, while treatment with both KU-60019 and IR
restored the BRCA1/Aurora A interaction. Collectively, these
results indicate that BRCA1 and Aurora-A interact in hESCs, and
that ATM activation disrupts this relationship.

IR decreases Aurora A-mediated phosphorylation of S308-BRCA1.
Concurrent inhibition of ATM reverses this effect.

The interaction between BRCA1 and Aurora A results in Aurora A
phosphorylating BRCA1 at Serine 308, and this post-translation
modification is important for mitotic entry regulation (Ouchi et
al., 2004). This result has been independently validated and
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experimental results have also shown that BRCA1 phosphorylation
by Aurora A is important for BRCA1’s retention at centrosomes
(Brodie and Henderson, 2012) as well as its regulation of
mitotic microtubule nucleation (Sankaran et al., 2005).
Therefore, it is likely that by disrupting the interaction of
BRCA1 and Aurora A, ATM is preventing Aurora A from
phosphorylating BRCA1. To test this hypothesis, we first
immunoprecipitated endogenous BRCA1 from hESC lysates that were
treated the same way as in previous experiments (with or without
KU-60019 and/or 5 Gy IR). As shown in Figure 4.4, the DNA damage
caused by IR drastically reduced the amount of p-S308-BRCA1.
This effect was reversed by ATM inhibition, indicating that ATM
activation not only disrupts the BRCA1/Aurora A interaction, it
also prevents the BRCA1 serine phosphorylation that is important
for mitotic regulation and entry.

Expression of a non-phosphorylatable BRCA1 mutant mimics the
ATM-inhibited phenotype.

In order to corroborate the results obtained with the
pharmacologic inhibition of ATM, we created a FLAG-tagged mutant
version of BRCA1 in which four critical serine residues (targets
of both ATM and ATR) are mutated to alanine (referred to as the
“4P” mutant) (see Figure 4.5 for a schematic of the plasmids
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used). If our hypothesis is correct, and the extensive
phosphorylation of the SQ cluster of BRCA1 prevents the entry
into mitosis, then cells transfected with the 4P mutant should
display defects in cell cycle arrest. Both FLAG-tagged wild type
(WT) BRCA1 and the 4P mutant were transfected into 293T cells to
check for expression. Once it was confirmed that the plasmids
translated and transcribed appropriately (Figure 4.6A), they
were transfected into hESCs using SuperFect. In un-irradiated
cells, the 4P-mutant cells had a higher (though not significant)
mitotic index than the WT cells. However, after 5 Gy IR, 4P
cells had a significantly higher mitotic index when compared to
WT cells (an almost 4-fold increase) (Figure 4.6B).
Interestingly, the 4P cells (both control and irradiated)
demonstrated an obvious reduction in cell number, indicating the
serine-to-alanine mutations were somewhat toxic to the cells.
Presumably, the high basal levels of p-BRCA1 in hESCs somehow
promotes survival, either through enhanced DNA repair, more
efficient cell cycle checkpoints, or some combination of the
two.
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Chapter Summary

While the experimental results presented in Chapter 3 clearly
demonstrate that ATM regulates the entry into and the
progression through mitosis in hESCs, the mechanism by which it
exerts this control is unknown. As discussed earlier, it is well
established that activated ATM phosphorylates BRCA1, and there
have been several papers published which demonstrate that BRCA1
plays a role in regulating the G2/M checkpoint. One pathway by
which BRCA1 controls G2/M arrest is through its interaction with
Aurora A. As Aurora A binds to and interacts with BRCA1 in the
SQ cluster domain (the target of ATM’s kinase activity), we
turned our attention to BRCA1 and Aurora A in order to clarify
how ATM activation affects this relationship and the transition
into mitosis.

The data presented in Chapter 4 indicates that ATM activation
increases the phosphorylation of BRCA1, an event that is blocked
by the addition of our ATM inhibitor, KU-60019. Interestingly,
there appears to be a relatively high level of p-BRCA1,
regardless of ATM activation or inhibition. This steady amount
of phosphorylation on other downstream ATM-targeted proteins has
not been seen in our hands, though we have investigated this in
the past (Adams et al., 2010a, 2010b). As it is extremely
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important for hESCs to maintain their genetic integrity, perhaps
a constitutively phosphorylated/activated BRCA1 enhances its
ability to detect and repair potentially harmful lesions in the
DNA. Additionally, the high basal level of phosphorylation could
account for the relative “leakiness” of the G2/M checkpoint that
was shown in Chapter 3. If the phosphorylation of BRCA1 is
important for checkpoint activation, but there is already a high
level of p-BRCA1, then maybe the additional phosphorylation
brought on by DNA damage is only partially successfully in
arresting the cell – a case of not being able to see the forest
for the trees.

We were able to see BRCA1 and Aurora A interacting in hESCs,
though this was only witnessed during the early-to-mid phases of
mitosis. The most interesting result of these experiments was
the relative failure of the endogenous BRCA1/Aurora A coimmunoprecipitation using the Santa Cruz C-20 BRCA1 antibody,
arguably the most published, most successful BRCA1 antibody that
is available. While BRCA1 could be routinely immunoprecipitated
from hESC lysates, a constant, similar level of Aurora A coimmunoprecipated with it, regardless of treatment. The fact that
we were only able to tease out differences using the p-S1423BRCA1 antibody suggests several possibilities. First, based on
the results obtained in Figure 4.1 A and B, there seems to be a
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small population of un-phosphorylated BRCA1 in hESCs. Perhaps
this population always interacts with Aurora A, regardless of
other events occurring in the cell. Second, many papers have
been published describing BRCA1 interacting with a wide variety
of proteins. The C-20 antibody recognizes the C-terminus of BRCA
– the region in which many proteins have been shown to bind.

It

could be that, in hESCs, it is a simple case of too many
partners interacting with BRCA1, preventing the antibody from
recognizing its substrate. By using the p-S1423-BRCA1 antibody,
we are trying to grasp on to a different “handle” of BRCA1 – one
that is more successful. The fact that even after 5 Gy of IR
there was still a small amount of Aurora A coimmunoprecipitating with p-BRCA1, and a small level of p-S308BRCA1 detected, further corroborates the results presented in
Chapter 3 which suggest that hESCs have a relatively weak G2/M
checkpoint.

As artificial modulation of ATM activity can prolong the stages
of mitosis (described in Chapter 3) as well as the BRCA1/Aurora
A interaction, perhaps the extra time measured is a result of
abnormal microtubule nucleation instead of (or, in addition to)
the cell “missing” DNA damage and letting the cycle continue.
Without ATM becoming activated and blocking Aurora A from
interacting with and phosphorylating BRCA1, BRCA1’s ubiquitin
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ligase activity remains unregulated and appropriate numbers of
microtubules are not formed in a reasonable amount of time. By
preventing ATM from phosphorylating BRCA1, the cell builds
excessive amounts of the mitotic architecture (even in the face
of DNA damage), and while it can successfully traverse mitosis,
it does not do so without significant setbacks. Additionally,
BRCA1 functions to prevent abnormal centrosome amplification.
The recorded aneuploidy that results from continuous ATM
inhibition (Chapter 3) might well be a result of the cell’s
failure to regulate BRCA1 and thus, more than two centrosomes
per dividing cell are created, leading to multi-polar asters and
the development of aneuploidy.

Finally, seeing similar results with the 4P BRCA1 mutant
transfected hESCs (as compared to the ATM-inhibited treated
cells) is promising, though this method is not without its
drawbacks. Chief among the issues raised by assaying cells in
this manner is the fact that the hESCs used continue to express
their own endogenous and fully phosphorylatable BRCA1. However,
similar experiments are currently being conducted in BRCA1-null
ovarian cancer cells, and our results in these cells (deficient
cell cycle checkpoints and DNA repair) have generally replicated
what we have seen in hESCs (Dever, Beckta et al, in
preparation).
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The data presented in this chapter provides one plausible
mechanism by which ATM activation causes G2/M arrest. It is
likely that, similar to their differentiated cousins, many
different proteins and pathways contribute to cell cycle arrest
in pluripotent cells. These other pathways remain open for
future study.

134

Chapter 5:
Conclusions
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This work has demonstrated a clear role for the ATM kinase in
human embryonic stem cells. ATM activates in response to both
decatenation inhibition as well as irradiation-induced DNA
damage, and this activation results in a G2/M arrest. Treatment
of hESCs with a potent ATM-inhibitor, KU-60019, abrogates this
arrest and allows cells to enter mitosis. Once past the G2/M
checkpoint, ATM-inhibited cells experience a significantly
prolonged mitosis, and concurrent inhibition of decatenation
results in many instances of endoreduplication (where cells
which have already copied their DNA enter mitosis, and, upon
failing to separate appropriately, re-enter the cell cycle with
a tetraploid amount of DNA). In line with this observation,
continuous pharmacologic inhibition of ATM results in a
significant increase in the average number of kinetochores per
cell, indicating a stable gain of DNA content.

The experiments presented here indicate that one possible
mechanism by which ATM enacts a G2/M arrest is through
disrupting the BRCA1/Aurora A interaction. BRCA1’s E3 ubiquitin
ligase activity is important for regulating centrosome
duplication (ensuring that only one centrosome copy is made per
cell per cycle), as well as microtubule nucleation (the process
by which microtubules are assembled from y-tubulin building
blocks). When activated, ATM phosphorylates the SQ cluster
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domain of BRCA1, the region in which Aurora A binds. This
phosphorylation prevents Aurora A from interacting with BRCA1
and, thus, prevents Aurora A from phosphorylating BRCA1 on S308,
a modification which inhibits BRCA1’s inhibition of microtubule
formation. Without this phosphorylation, an adequate number of
microtubules cannot be constructed, preventing the cell from
entering mitosis. Our proposed model of G2/M arrest in hESCs can
be visualized in Figure 5.1.

This mechanism lends itself well to some of the current theories
of centrosomal participation in the DNA damage response and cell
cycle checkpoint regulation. Like DNA, centrosomes are
replicated once per cycle (in S phase), and this replication
occurs in a semi-conservative manner. At the onset of mitosis,
these two centrosomes separate, forming the iconic poles of the
mitotic spindle (Löffler et al., 2006). One direct mechanism by
which G2 arrest can be enacted is through the inhibition of this
centrosomal separation. This response occurs in an ATM-dependent
manner, and is mediated by a protein called Nek2 (Fletcher et
al., 2004; Hinchcliffe et al., 2001), a kinase whose activity
causes a loss of centriole cohension and leads to the
centrosomal separation (Fry et al., 1998; Helps et al., 2000;
Mayor et al., 2000).
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Going beyond direct regulation as a means of arrest, several
laboratories have put forward the hypothesis that centrosomes
act as “command centers” for cell cycle control (Doxsey, 2001;
Doxsey et al., 2005; Krämer et al., 2004). Many proteins
involved in both the DNA damage response as well as cell cycle
regulation have been found to localize to and interact with each
other around centrosomes, in times of both stress and normal
growth. It seems as if centrosomes act as some sort of
spatiotemporal organizing center for growth control and stress
response – a place where proteins can go to communicate and
“make decisions” about whether or not to proceed in cycling (see
(Löffler et al., 2006), for perspective). Additionally,
centrosomes can act as a place for the cell to sequester
proteins to allow cycling to continue even in the presence of
damage. One study performed in mESCs found the key cell cycle
checkpoint protein Chk2 was localized to and retained at
centrosomes, preventing it from activating a G1/S checkpoint
(Hong and Stambrook, 2004). Interestingly, this effect could be
overcome through ectopic expression of Chk2, indicating that it
was indeed the centrosomal sequestration that was abrogating the
G1/S checkpoint. Our model of ATM regulating BRCA1/Aurora A as a
means of checkpoint control fits in well with these previously
published studies.
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One potential issue with the experiments presented within this
dissertation is our reliance on pharmacologic inhibition of ATM,
as opposed to siRNA-mediated knockdown. However, we feel that
the use of a drug as opposed to knockdown provides several key
benefits for our studies. Most importantly, it avoids the major
toxicity we experience when attempting to transfect siRNA into
hESCs. While it is possible to strike a balance between
efficiency and toxicity, this balance usually leaves us with
inadequate cell numbers to derive any meaningful conclusions. We
have also found that the stress of transfection can occasionally
cause differentiation, further discouraging the use of siRNA.
Additionally, as we have shown KU-60019 to be extremely
effective even at nanomolar concentrations (Golding et al.,
2009), we can be reasonably sure that close to 100% of the cells
are experiencing partial-to-complete inhibition of ATM, whereas
it is highly unlikely that we could achieve such numbers with
siRNA. Finally, the inhibitor can be used to quickly and
transiently inhibit ATM. This avoids having to wait several days
for the siRNA to exert its knockdown effect and allows us to
conduct experiments in which the pharmacologic inhibition of ATM
can be reversed (as was done in the kinetochore
staining/aneuploidy assay in Chapter 3).
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The use of a small molecule inhibitor of ATM versus protein
knockdown in signaling studies does raise unique issues. In
2010, Chris Bakkenist’s lab demonstrated that pharmacologic
inhibition of ATM does not have the same phenotype as ATM
protein knockdown or mutation (White et al., 2010). They
speculate that this observation is the result of the kinaseinhibited ATM still being able to localize to and function
structurally at sites of DNA DSBs (Choi et al., 2010). It is
likely that this non-functional version of ATM serves as a
physical barrier, preventing any “back-up” proteins from coming
in and picking up some of the slack for the malfunctioning ATM
kinase.

This could account for some of the differences seen in the
literature between investigators examining ATM’s function using
either knockdown or small molecule inhibitors. For example, a
paper recently published in Cell demonstrated that Aurora B
phosphorylates ATM at S1403 during mitosis (in the absence of
DNA damage) (Yang et al., 2011). Interestingly, these
researchers found that ATM-null or -mutant cells had a
significantly shortened progression through mitosis when
compared to wild-type cells. This is in direct contrast to the
findings presented in Chapter 3, where pharmacologic inhibition
of ATM in hESCs significantly prolonged the time of mitosis.
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Similar to “blocking” events at DSBs, kinase-inhibited ATM could
still localize to and interact with key mitosis-promoting
proteins, preventing the correct sequence of events and
prolonging the mitotic sequence. Perhaps conducting studies
using both protein knockdown and small molecule inhibitors could
grant us greater insight into the true functions of ATM and
other proteins.
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Future Directions

As with any scientific investigation, the findings presented
here only leave us with more unanswered questions. As such,
there are still several ongoing experiments in this project that
are not yet complete. The results of these studies will
hopefully further clarify and reinforce that data which has
already been presented.

First, more work needs to be done with the BRCA1 wild-type and
4-phospho-mutant constructs. If our hypothesis is correct, then
the 4-phospho-mutant transfected cells should replicate most, if
not all, of the ATM-inhibited cell cycle data. In parallel with
this project, we have been using these BRCA1 constructs in a
BRCA1-null ovarian cancer cell line to investigate similar
endpoints (Dever & Beckta, in preparation). The data we have
derived from these cancer cells have, so far, supported the data
we have obtained in the hESCs. Most importantly, we need to
demonstrate (using hESCs) that the 4-phospho-mutant BRCA1 can be
immunoprecipitated, and that, when compared to wild-type BRCA1,
more Aurora A is co-immunoprecipitated with it.
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Second, we are in the process of creating an S308N-BRCA1 mutant
construct to transfect into the stem cells. This version of
BRCA1 should be unphosphorylatable by Aurora A, leaving BRCA1
free to ubuiqitinate y-tubulin as much as possible. These S308N
cells should phenocopy cells that have undergone ATM activation
and arrest in G2/M. Unfortunately, it is likely that mimicking
chronic ATM activation will lead to heavily arrested growth (or
massive death), and it might be difficult to assay these cells
appropriately.

Finally, it would be interesting to repeat many of these studies
(as well as our original studies examining the dynamic role of
ATM and ATR in the DNA damage response) in human iPS cells. We
have recently acquired well-characterized iPS cells from the
Children’s Hospital of California (Stover et al., 2013), which
have already been adapted to our xenobiotic-free culture
protocols. These cells are an ideal way to translate our methods
into a new pluripotent system within which we can continue to
rigorously test our hypotheses.

The work presented here continues to build upon the solid
foundation of literature which has shown, time and time again,
that our understanding of molecular signaling begins to break
down when hESCs are involved. Pluripotent cells appear to be
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governed by a different set of rules than their differentiated
counterparts, and we still have much to learn. Clearly, a
significant effort is needed to enhance our knowledge of the
basic biology of these cells if we hope to employ them
successfully in the clinic.
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